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1 Introduction 
 
1.1 The multifunctional cytokine IL-6 
 
The pleiotropic cytokine Interkeukin 6 (IL-6) was molecularly cloned in 1986 (1) and was 
originally identified as an antigen-nonspecific B-cell differentiation factor that activates B-
cells to produce immunoglobulins (2). Today it is known that IL-6 provides a wide range of 
biological activities in immune regulation and it is secreted by various lymphoid cell types, 
such as T-cells, B-cells, macrophages and monocytes (3). Possessing autocrine, paracrine, and 
endocrine functions, it acts as a major regulator of the hepatic acute phase response by 
stimulating hepatocytes to produce C-reactive protein, fibrinogen and serum amyloid A (4). It 
induces growth of T-cells and differentiation of cytotoxic T-cells by enhancing the expression 
of IL-2 receptor and the production of IL-2 (5); further IL-6 induces differentiation of 
macrophages (6) and megakaryocytes (7). In addition, circulating IL-6 together with tumor 
necrosis factor α (TNF-α) and interleukin-1 (IL-1) cause fever and leukocytosis which is 
beneficial for pathogen elimination (8, 9).  
Due to its potent ability to activate host immune response after infection, IL-6 expression is 
tightly regulated and the protein is almost not expressed under normal conditions. It is 
commonly produced at local tissue sites and is released in almost all situations of homeostatic 
perturbation, which include acute infection, trauma and endotoxaemia. IL-6 can also become 
chronically elevated, resulting in the prolonged activation of its biological activities. This 
dysregulation in IL-6 levels can then turn the initially beneficial responses into deleterious 
conditions. 
Apart from lymphoid cells, IL-6 is produced also by various types of nonlymphoid cells, such 
as fibroblasts, keratinocytes, endothelial cells and several tumor cells (3). For instance, it has 
been shown that IL-6 levels are increased in the serum of patients suffering from colon 
carcinoma (10, 11). In addition, IL-6 has been identified as a growth factor for multiple 
myeloma cells (12) and renal cell carcinoma cells (13).  
Generation of IL-6 deficient mice has been achieved by the insertion of a neomycin-resistance 
gene into the first coding exon of the IL-6 gene. Homozygous IL-6 knockout mice develop 
normally but show a severely compromised acute phase response after tissue damage or 
infection. They are impaired in controlling infection with facultative intracellular bacteria like 
Listeria monocytogenes and show compromised T-cell dependent antibody response (14). 
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Furthermore, IL-6 knockout mice are completely protected from collagen-induced arthritis, a 
mouse model for arthritis (15) and they are resistant to experimental autoimmune 
encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein 
(MOG), an animal model for the demyelinating disease multiple sclerosis (16). Taken 
together, the phenotype of the IL-6 knockout mice highlights that IL-6 is an important 
cytokine involved in regulation of host response after infection and that disregulation of IL-6 
contributes to several pathological conditions in various diseases like arthritis or multiple 
sclerosis. 
 
1.2 IL-6 type cytokine mediated signal transduction 
 
Apart from IL-6, the IL-6 family comprises IL-11, viral IL-6, IL-27, IL-31, neuropoietin 
(NP), ciliary neutrotrophic factor (CNTF), cardiothropin-1 (CT-1), oncostatin M (OSM), 
leukaemia inhibitory factor (LIF) and cardiotrophin-like cytokine (CLC), which all share the 
common signal transducer glycoprotein 130 (gp130) as part of their receptor complexes (17). 
All IL-6 type cytokines belong to the long chain four α-helix bundle class of proteins, 
consisting of four long α-helixes termed A, B, C and D, which are arranged in an up-up-
down-down topology (18). Each of the IL-6 type cytokines is characterized by a certain 
profile of receptor recruitment that in all cases involves at least one molecule of gp130. IL-6, 
IL-11 and CNTF first bind specifically to their nontransducing co-receptor, called α-chain, 
which leads to the recruitment and dimerization of the signalling subunits gp130 and LIFRβ 
(19). IL-6 and IL-11 recruit two gp130 subunits and CNTF recruit one gp130 and one LIF 
receptor (LIFRβ) subunit. LIF, CT-1, IL-27, IL-31, viral-IL-6 and OSM can directly interact 
with their signalling receptor subunits without requiring an α-receptor (20-22). The cytokine 
CLC can only bind to the signal transducing subunits in the presence of an additional soluble 
cytokine receptor. CLC first binds to the soluble CNTFR (sCNTFR) or to the cytokine-like 
factor-1 (CLF-1) which leads then to recruitment of one gp130 subunit and one LIFRβ 
subunit (23, 24). Dimerization of the signal transducing chains gp130, LIFRβ, WSX-1, gp130 
like receptor (GPL) and OSM receptor (OSMR) brings the receptor associated tyrosine 
kinases, which belong to the Janus kinase (JAK) family, into close proximity leading to 
activation via inter- or intramolecular phosphorylation (25). There are six tyrosine residues in 
the intracellular part of human gp130 and at least five of the six cytoplasmic tyrosins are 
phosphorylated by the JAK kinases. Phosphorylation of the four distal tyrosines leads to 
recruitment and activation of the signal transducer and activator of transcription (STAT) 
Introduction 
 
  3 
proteins (26). To-date, seven mammalian STAT genes have been cloned and it is described 
that in response to IL-6 there is potent activation of STAT3 and to a minor extent activation 
of STAT1 (27, 28). Immediately after tyrosine phosphorylation, STATs form homo- and 
heterodimers and translocate to the nucleus where they recognise DNA binding sites in the 
promoter of their target genes (29). STAT3 DNA binding sites were shown, for example in 
the promotors of acute phase genes, such as C-reactive protein (30), α1-antichymotrypsin (31), 
and lipopolysaccaride-binding protein (32), and in the promotors of transcription factors, such 
as Jun B (33), c-Fos (34), interferon regulatory factor-1 (IRF-1) (35) and CCAAT enhancer 
binding protein δ (C/ERBδ) (36).  
In most systems the activation of STATs is transient. Inactivation of STATs is mediated by 
different pathways. One pathway is dephosphorylation of activated STATs by protein-
phosphatases. It was shown that activated STAT1 molecules promptly enter the nucleus and 
later return quantitatively to the cytoplasm as non-phosphorylated molecules (37). Recently a 
protein inhibitor of activated STAT3, named PIAS3, has been discovered in various human 
tissues. PIAS3 co-immunoprecipitates with tyrosine-phosphorylated STAT3 and blocks 
DNA-binding as well as gene activation of activated STAT3 (38). Another mechanism to 
down-regulate the STAT pathway has been discovered with the cloning and identification of 
suppressor of cytokine signalling (SOCS) proteins. These proteins represent negative-
feedback inhibitors, since their transcription is induced by IL-6 and LIF and since they inhibit 
tyrosine phosphorylation of gp130, STAT1 and STAT3 by directly interacting with the JAK 
kinases (39, 40). 
In addition to the JAK-STAT signal transduction pathway, it is known that the Ras mitogen-
activated protein (MAP) kinase pathway is also activated after IL-6 type cytokine stimulation. 
It has been shown that the Src homology protein 2 tyrosine phosphatase-2 (SHP-2) binds to 
phosphotyrosine-759 of gp130 (41) and leads via direct interaction with the adaptor protein 
growth factor receptor bound protein 2 (Grb2) to further activation of the Ras-Raf-MAPK 
pathway (42).  
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Figure 1: IL-6 family of cytokines and representation of the two major signal transduction pathways 
activated by IL-6.  
OSM signals via a gp130 and LIFRβ heterodimer or via a gp130 and OSMR heterodimer. Note: CNTFR is 
linked to the plasma membrane via a GPI-anchor. 
Abbreviations: FNIII: fibronectin type III, CBM: cytokine binding module (modified FNIII-domains), Ig: 
immunoglobulin, IL-6 RE: interleukin-6 response element. 
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1.3 The IL-6R 
 
The receptor complex mediating the biological activities of IL-6 consists of an 80 kDa IL-6 
binding glycoprotein termed IL-6 receptor-α (IL-6R) and the signal transducer gp130. The 
high affinity complex of [IL-6/IL-6R] interacts on target cells with at least two molecules of 
gp130 and leads to activation of signal transduction pathways (Figure 1). Gp130 is 
ubiquitously expressed on all cell types whereas the expression of the type-I-transmembrane 
protein IL-6R is restricted to some lymphoid cells like monocytes, macrophages, neutrophils, 
B-cells, subpopulations of T-cells and non-lymphoid cells like hepatocytes (43). The 
expression pattern of the IL-6R determines which cell types are responsive to the cytokine IL-
6, because cells that only express gp130 are unable to respond to IL-6. 
The extracellular part of the IL-6R consists of one immunglobulin-like domain (Ig-like 
domain) and two modified fibronectin-type III domains (FNIII-domains) which carry the 
cytokine binding motif tryptophan-serine-X-tryptophan-serine (W-S-X-S-W) and a set of four 
conserved tyrosine residues (44). IL-6 binding occurs between the two FNIII-domains 
whereas the Ig-like domain does not participate in cytokine binding. The FNIII-domains are 
followed by a long flexible stalk region, a transmembrane domain and a short intracellular 
domain which does not participate in signal transduction. Although the cytoplasmic part of 
the IL-6R is dispensable for receptor complex formation, it contains a tyrosine-based and a 
dileucine-type motif, which directs sorting of the IL-6R to the basolateral membrane of 
polarized cells (45). 
Beyond the membrane bound IL-6R form there are also two soluble isoforms of this receptor 
detectable in several body fluids, which lack the cytoplasmic and transmembrane domains. 
These isoforms are generated by two distinct mechanisms involving both posttranscriptional 
and posttranslational processes (46). Soluble IL-6R (sIL-6R) was detected in the plasma of 
healthy individuals at concentrations about 25-35 ng/ml (47). The sIL-6R can bind to its 
ligand IL-6 with comparable affinity as the membrane-bound isoform (48, 49). The complex 
of [IL-6/sIL-6R] associates with gp130 and activates target cells which do not express the IL-
6R. In contrast to other soluble receptors, such as the receptors for IL-1 or TNF-α, which are 
known to inhibit the effects of their ligands (50), sIL-6R acts agonistically on cells that 
express gp130. Activation of cells that only express gp130 via the [IL-6/sIL-6R] complex is 
called trans-signalling (50, 51) whereas activation of cells via the membrane-bound IL-6R in 
complex with IL-6 is called classic signalling (Figure 2).  
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The soluble IL-6R is generated by alternative splicing and ectodomain shedding. The 
differential mRNA splicing product codes for a reading frame shift and leads to the generation 
of a novel carboxy (COOH)- terminal protein sequence (GSRRRGSCGL), which has no 
influence on the biological properties of the sIL-6R in terms of ligand binding (52). 
Alternative spliced soluble cytokine receptors are described for many membrane-anchored 
proteins, like the LIFR, the epidermal growth factor (EGF) receptor and the CNTFR (50). 
Interestingly the second component of the IL-6 receptor complex, gp130, exists also in a 
soluble form (sgp130). Soluble gp130 is generated by alternative splicing (53) and there are 
relatively high circulating levels of sgp130 detectable in human blood (100-400ng/ml) (54). 
Since sgp130 binds the complex of [IL-6/sIL-6R] it has been concluded that this soluble 
cytokine receptor is a natural inhibitor of IL-6 trans-signalling (49, 55, 56).  
Additionally, the soluble form of the IL-6R can also be produced by limited proteolysis of the 
membrane-anchored IL-6R resulting in the release of the ectodomain in the extracellular 
space and a short C-terminal fragment (CTF) remaining in the plasma membrane (53). The 
enzymes which are involved in the limited proteolysis of the IL-6R belong to the “A 
Disintegrin And Metalloproteinase Domain” (ADAM) family of metalloproteases. ADAM 
proteases are membrane anchored but also found as soluble proteins, and are characterized by 
the presence of a Zn2+- protease domain (57). Limited proteolysis of transmembrane proteins 
is also termed “shedding” and is a very important mechanism regulating and modulating cell 
signalling events mediated for example by TNF-α, IL-1R, L-Selectin, cadherins and amyloid 
precursor protein (APP) (58, 59).  
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Figure 2: Classic signalling versus trans-signalling.  
Cells that express both gp130 and the IL-6R are responsive to IL-6 (classic signalling). Cells that express only 
gp130 can be activated by the complex of [IL-6/sIL-6R]. Activation of such cells is termed trans-signalling. 
There are two mechanism involved in sIL-6R generation. The soluble IL-6R can be generated by proteolytic 
cleavage. Members of the ADAM-protease family are involved in shedding of the IL-6R. Differential splicing 
leads to two distinct IL-6R mRNA transcripts: one encodes for the soluble IL-6R and the other for the 
membrane-anchored protein. Note: alternative splicing leads to a unique COOH-terminal sequence 
[GSRRRGSCGL]. 
 
 
1.4 The soluble IL-6R in chronic inflammatory diseases 
 
The soluble isoforms of the IL-6R can be generated by alternative splicing or by proteolytic 
cleavage of the membrane-bound precursor from cells expressing the cognate receptor (Figure 
2). There are several studies in which levels of the soluble IL-6R were measured during 
pathological conditions and in many cases there is a direct correlation between severity of the 
disease and elevated sIL-6R levels. Further, it has been shown that IL-6 trans-signalling rather 
then IL-6 classic signalling (60) is involved in the pathogenesis as well as in the persistence of 
these diseases. 
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Rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA) are inflammatory diseases 
characterized by destruction of bones and cartilage of affected joints mediated by 
dysregulation of inflammatory cytokines (61). IL-6 is one of these cytokines and its 
overproduction appears to be responsible for many clinical symptoms in RA. During RA there 
are not only elevated levels of the cytokine IL-6 detectable but also significant higher 
amounts of the sIL-6R (62, 63). Examination of IL-6 and sIL-6R concentrations in synovial 
fluid from arthritic patients showed that the extent of joint destruction correlates with the 
increased concentration of both proteins (64). Treatment of RA patients with a neutralizing 
humanized anti-IL-6R antibody leads to significant reduced disease symptoms like decreased 
serum CRP and fibrinogen levels and reduced thrombocytosis and hypoalbuminemia (65). 
Although the cellular origin of sIL-6R in arthritis remains unknown, it is assumed that sIL-6R 
is released by proteolytical cleavage from activated leukocytes, which infiltrate the joints 
(66). 
Multiple myeloma is a malignant disorder caused by uncontrolled proliferation of plasma 
cells; patients suffering from this disease, show significantly elevated sIL-6R serum levels 
(67, 68). Again, the severity stage of multiple myeloma appears to correlate with circulating 
sIL-6R levels (69) and there are reports that physiological concentrations of sIL-6R increase 
the sensitivity of myeloma cells to IL-6 (70).  
Crohn’s disease (CD) is a chronic inflammatory condition of the gastrointestinal tract, where 
it has been shown that type-1 T-helper cells (TH1-cells) are involved in disease manifestation. 
IL-6 trans-signalling contributes to CD by preventing T-cell apoptosis and elevated 
concentrations of both IL-6 and sIL-6R have been measured in patients suffering from this 
disease. IL-6 in combination with the sIL-6R leads to activation of STAT3 signalling and the 
upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-XL in mucosal T-cells (71). A 
neutralizing antibody against the IL-6R suppresses CD in various animal models by inducing 
apoptosis of lamina propria T-cells (72).  
To determine the role of the sIL-6R in vivo, transgenic mice were constructed expressing 
either human IL-6 alone or together with human soluble IL-6R. Due to the observation that 
murine IL-6 is unable to bind the human IL-6R, trans-signalling mediated by the human 
soluble IL-6R is only taking place in the double transgenic mice (73). The phenotype of the 
IL-6/sIL-6R transgenic mice revealed increased hepatic and splenic hematopoiesis, 
hepatocellular hyperplasia and plasma cell proliferation. Major findings were also that 
transgenic expression of the sIL-6R makes animals more sensitive to the cytokine IL-6 and 
that the plasma half-life of IL-6 is significantly prolonged (74). 
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1.5 Generation of the soluble IL-6R 
 
Although under several pathological conditions elevated levels of the sIL-6R have been 
described (75), there is still little understanding about the regulation of sIL-6R release. In 
many cases it is unclear whether the impact of the sIL-6R in various diseases depends on 
locally or systemic elevated sIL-6R levels. 
Soluble IL-6R can be released from the cell surface by proteolytical cleavage of the 
membrane-anchored precursor protein. This process is referred to as “shedding”. Shedding of 
the IL-6R is strongly induced by phorbol ester e.g. PMA which are known to activate protein 
kinase C (PKC) (76). Shedding is completely inhibited in the presence of hydroxamic-acid 
based inhibitors, which potently inhibit metalloproteases. The IL-6R is a substrate of the 
metalloprotease ADAM10, which appears to be responsible for the constitutive shedding, and 
for ADAM17 also referred to as tumor necrosis factor-α converting enzyme (TACE), which is 
involved in stimulated shedding (77).  
Besides of phorbol esters, there are also other stimuli described, which lead to enhanced 
ectodomain shedding of the IL-6R. It has been shown that the acute-phase protein CRP 
induces shedding of the IL-6R resulting in a threefold increase in sIL-6R levels after 30 to 60 
minutes exposure on human neutrophils. Although, alternative mRNA splicing was excluded 
as mechanism involved in sIL-6R production after CRP stimulation, hydroxamate compounds 
had also only a minor effect suggesting that other proteases are involved in this process. Thus, 
CRP acts not only as an acute-phase reactant, but it contributes to formation of the agonistic 
sIL-6R/IL-6 complex (78). Indeed, CRP levels in several diseases have been found to 
correlate with those of sIL-6R (69). Interestingly, a study on the human osteoblast-like cell 
line MG63 revealed that the proinflammatory cytokines IL-1β and TNF-α induce IL-6R 
shedding. This effect was not influenced by cycloheximide excluding de-novo protein 
synthesis but was markedly inhibited by hydroxamate compounds and transfection of TACE 
siRNA (79). Thus, not only the inflammatory mediator CRP has the potential to influence 
sIL-6R release but also IL-1β and TNF-α, indicating that both cytokines are likely to increase 
sIL-6R levels in vivo which could lead to osteoclast-like cell formation in inflammatory 
conditions like rheumatoid arthritis. 
Except of inflammatory mediators it was also shown that bacterial proteins have an impact on 
IL-6R shedding. The pore forming bacterial toxins Streptolysin O (SLO) and Hemolysin A 
(HlyA), which disturb membrane lipid asymmetry, were found to induce massive shedding of 
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IL-6R from transfected Cos-7 cells and human macrophages. Toxin-induced shedding was not 
sensitive to the PKC inhibitor staurosporin but was prevented by the hydroxamate TAPI (80). 
Interestingly, alteration of the plasma membrane composition by cellular cholesterol depletion 
also leads to enhanced IL-6R shedding. Again this stimulation was PKC-independent but 
hydroxamate sensitive (77). 
The IL-6R is not only a target substrate for membrane-anchored metalloproteases belonging 
to the ADAM-family, but can also been cleaved by bacterial secreted proteases. Serralysins 
are metalloproteases, which are secreted by various pathogenic bacteria. Interestingly, 
Serratia marcscens metalloprotease (SMP) was found to release biological active sIL-6R 
from human monocytes. That effect was inhibitable with TAPI. The study revealed that the 
bacterial protease, cleaved the IL-6R at a site distinct from that utilized by the endogenous 
proteases (81). Further, it was demonstrated, that proteases belonging to the serine-family 
contribute to shedding of the IL-6R. Activated neutrophils, which infiltrate the site of tissue 
destruction, secrete high amounts of the serine proteases elastase and cathepsin G and it was 
shown that elastase is involved in sIL-2R release whereas cathepsin G selectively used the IL-
6R as a substrate (82). 
 
1.6 The tumor necrosis factor-α converting enzyme (TACE) 
 
TACE was characterized and cloned in 1997 and was identified as the secretase responsible 
for releasing pro-TNF-α from the cell membrane (83, 84). Since then, the understanding of 
TACE biology has grown steadily and today many substrates for this protease have been 
identified. Among them are proteins, which play a pivotal role in cell development, 
differentiation, immune regulation and adhesion (Table 1). 
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Development and differentiation Immune system Other 
TGFα (85) 
EGF/ΗΒ-EGF (86) 
amphiregulin (87) 
neuregulins (88) 
TrkA (89) 
GHR (90) 
Notch (91) 
pro-TNF-α (83) 
TNFRI/II (92) 
L-secectin (93) 
IL-6R (77, 94) 
fractalkine (95) 
IL-1RII (96) 
M-CSF-R (97) 
IL-15R (98) 
APP (99) 
PrPc (100) 
MUC1 (101) 
Collagen XVII (102) 
 
Table 1: TACE substrates.  
Abbreviations: APP: amyloid precursor protein, EGF: epidermal growth factor, HB-EGF: heparin-binding EGF-
like growth factor, GHR: growth hormone receptor, IL: interleukin, MUC1: mucin1, M-CSF-R: macrophage-
colony stimulating factor-receptor, PrPc: cellular prion protein, TGF: transforming growth factor, TNF: tumor 
necrosis factor, TrkA: neurothrophic tyrosine kinase type 1, TNFR: TNF receptor. Adopted from (103). 
 
 
TACE belongs to a superfamily of zinc dependent proteases known as metzincins. Based on 
sequence and structural similarities, metzincins are grouped in four distinct subfamilies: the 
astacins, the matrix metalloproteinases (MMPs), the adamalysins (snake venom 
metalloproteinases and ADAMs) and the serralysins (bacterial proteases) (104). ADAMs are a 
family of metalloproteases with high sequence homology to the snake venom 
metalloproteinases (SVMPs) (105). The term ADAM stands for A Disintegrin And 
Metalloproteinase, which represents two key structural domains of this molecule. ADAMs are 
type-I transmembrane-proteins, which contain a prodomain as well as metalloprotease, 
disintegrin, cysteine-rich, EGF-like and cytoplasmic tail domains. ADAM17 (TACE), 
ADAM9 and ADAM10 (Kuzbanian) mediate the shedding of cell surface molecules and are 
called sheddases (106). 
TACE is synthesized as a zymogen with the prodomain acting as an inhibitor of the protease 
activity via the cysteine switch mechanism. The free cysteine residue located in the 
prodomain coordinates with the zinc in the active site of the protease and prevents enzymatic 
activity (83). During TACE maturation the prodomain is removed. The furin cleavage site (R-
V-K-R) localized between the pro and the catalytic domain is responsible for the generation 
of biologically active TACE (Figure 3). The metalloprotease domain contains the zinc-
binding consensus motif H-E-X-G-H-X-X-G-X-X-H-D (104) involved in coordinating zinc 
with histidine residues and creating the active site of the enzyme. The function of the 
disintegrin, EGF-like and cysteine-rich domain of TACE is not well determined. The 
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cytoplasmic tail is likely to be a target for kinases because it contains putative MAPK-, PKC-, 
and casein kinaseII phosphorylation sites (107, 108). 
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Figure 3: Schematic representation of the domain architecture of the ADAM metalloproteases. 
All known ADAMs are expressed as inactive (latent) zymogens and require cleavage of a propeptide domain for 
activation. This propeptide contains a well-conserved cysteine which is involved in Zn2+ coordination and is 
responsible for the latency of the enzyme. After cleavage of the prodomain at the furin cleavage site (R-V-K-R), 
H2O as the fourth ligand in Zn2+ coordination is recruited to the catalytic core and the enzyme is now present in 
its active form. Abbreviations: EGF: epidermal growth factor, S: sulfur, TM: transmembrane. 
 
 
Although TACE is an important protein with various biological functions, which is 
underlined by the prematured death of mice lacking TACE activity (TACEΔZinc/ΔZinc mice 
(83)) the activation mechanism of this enzyme remains largely unknown. Shedding of TACE 
substrates can be stimulated by PMA, a non-physiological stimulator of PKC indicating that 
phosphorylation of the cytoplasmic tail of TACE by PKC may be a potential regulatory 
mechanism. There are also studies, which show that activation of the MAP kinase pathway 
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leads to TACE activation by direct association and phosphorylation of the Erk kinase with the 
cytoplasmic domain of TACE (108). However, it has also been shown that a truncated TACE-
construct lacking the whole cytoplasmic domain retains the ability to induce phorbol ester-
stimulated shedding of various substrates suggesting that the cytoplasmic domain is 
dispensable for TACE activation (92).  
In several studies it was demonstrated that cross-talk between G protein-coupled receptor 
(GPCR) and epidermal growth factor receptor (EGFR) requires TACE mediated cleavage of 
EGF-like growth factor precursors. TACE is involved in the cleavage of amphiregulin, HB-
EGF, Epigen, Epiregulin and TGFα. (86). A recent study provides evidence that downstream 
activation of the PI3-kinase by GPCRs leads to recruitment of PDK1 to the plasma membrane 
where PDK1 binds and phosphorylates the cytoplasmic domain of TACE. This 
phosphorylation event leads to subsequent activation of TACE, which results in EGF-ligand 
precursors cleavage and EGFR activation (109). Further, it was shown that nitric oxid and 
reactive oxygen species (ROS) were involved in TACE activation. The proposed mechanism 
was that this compounds lead to oxidation of the cysteine, which is located in the inhibitory 
prodomain of TACE and participates in zinc coordination thereby resulting in releasing the 
active form of the enzyme (110). Interestingly, studies involving L-selectin shedding on 
human neutrophils demonstrate that some non-steroidal anti-inflammatory drugs (NSAIDS) 
are involved in TACE activation. Importantly, only NSAIDS, which had the potential to 
decrease cellular ATP levels induce L-selectin shedding, which leads to the hypothesis that 
TACE activation is prevented by an ATP-dependent mechanism (111). Recently it was shown 
that ADAM metalloproteases are activated during staurosporin- or campthothecin-induced 
apoptosis of epithelial cells thereby releasing the ectodomain of the cell adhesion molecule E-
cadherin (112). However, the molecular mechanism leading to ADAM activation during 
apoptosis remains elusive. 
 
1.7 Apoptosis 
 
Apoptosis defines the programmed cell death, a process by which a cell dies in a regulated 
and organized fashion (113). As important as cell division, regulated cell death allows the 
organism to tightly control cell numbers and tissue size and to clear abnormal cells. Apoptosis 
is characterized by dramatic morphological and biochemical changes, which were distinct 
from the features observed in cells undergoing pathological, necrotic cell death (114). The 
typical features of cells dying apoptotically comprise nuclear condensation, intranucleosomal 
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DNA fragmentation, membrane blebbing, compaction of cytoplastic organelles, decrease in 
cell volume and loss of plasma membrane phosphatidylserine (PS) asymmetry (115). PS 
externalization serves as a specific recruitment signal for phagocyte docking and subsequent 
engulfment and degradation of the apoptotic cell, preventing an inflammatory response (116). 
Most of the morphological changes observed during programmed cell death are initiated by 
cysteine proteases that are activated specifically in apoptotic cells. These death proteases act 
as central executioners of the apoptotic pathway and are part of a large protein family known 
as the caspases (117). All known caspases possess an active-site cysteine and cleave 
substrates after an aspartic acid residue (Asp-X-X-X). However, the substrate specificity of 
different caspases is determined by the four residues amino-terminal to the cleavage site 
(118).  
Caspases are highly conserved through evolution, and can be found from humans, to insects, 
nematodes and hydra (119, 120). Eliminating caspase activity, either through mutation or the 
use of small pharmacological inhibitors, has been shown to slow down or even prevent 
apoptosis (121).  
As many enzymes, caspases are expressed constitutively as inert zymogens and consist of 
three domains: an amino-terminal prodomain, and the p20 and p10 domains. Both, the p10 
and p20 domains, are found in the mature enzyme and in all caspases examined so far, the 
catalytic active enzyme is a heterotetramer containing two p20/p10 heterodimers (122). Most 
caspases are activated by proteolytic cleavage of the zymogen between the p20 and p10 
domains and usually also between the prodomain and the p20 domain. Caspases are released 
in their active form by different mechanisms involving proteolytic cleavage of the zymogen, 
by previously activated caspase molecules, by autocatalytic cleavage or by association with 
regulating protein cofactors (122).  
Initiator caspases are the first to be activated during programmed cell death and include 
caspase-2, -8, -9 and -10. These cleave and activate the effector caspases-3, -6 and -7, which 
are responsible for the digestion of many cytosolic and nuclear key proteins, such as the 
nuclear enzyme poly (ADPribose) polymerase (PARP), histone H1, lamin B, actin, fodrin, 
PKCδ and retinoblastoma protein (Rb). Cleavage of the effector caspase substrates leads 
finally to all typical biochemical and morphological changes observed in apoptotic cells (123-
128). 
Caspase activation during apoptosis occurs via two major pathways. The extrinsic pathway 
involves the binding of death ligands to cell surface receptors (e.g. CD95/Fas receptor or TNF 
receptor), which leads to recruitment of adaptor molecules and to formation of a death 
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inducing signalling complex (DISC) at the plasma membrane (129). Formation of the DISC 
leads to recruitment, oligomerization and activation of pro-caspase-8 by autocatalytic 
cleavage. Once activated, caspase-8 cleaves and activates the effector caspases, thereby 
inducing the cell death program. 
The intrinsic pathway is initiated through the release of cytochrome c from the intermembrane 
space of mitochondria in response to apoptotic stimuli diverse as DNA-damage, UV 
irradiation or cytokine deprivation (130). Once translocated to the cytosol, cytochrome c 
binds to apoptosis protease activating factor-1 (APAF-1) and in the presence of ATP 
facilitates APAF-1 oligomerization and the recruitment of pro-caspase-9 (131). The formation 
of this caspase-activating complex is termed the apoptosome. Once bound to the apoptosome, 
caspase-9 is activated, and subsequently triggers a cascade of effector caspase activation and 
proteolysis, leading to apoptotic cell death (132). 
Besides the caspases as major executioners, the family members of the Bcl-2 proteins 
represent the major regulatory molecules of programmed cell death. The cell death-regulating 
activity of the Bcl-2 proteins depend on their ability to modulate mitochondrial functions by 
regulating the release of pro-apoptotic factors like cytochrome c (133-135). Bcl-2 family 
members are divided into pro- and anti-apoptotic molecules. The family of pro-apoptotic Bcl-
2 molecules comprises Bax, Bak, Bnip3, Nix/Bnip3L, Bid, Noxa, Puma and Bad whereas the 
family of anti-apoptotic molecules is smaller and comprises Bcl-XL, Mcl-1, and Bcl-2 (136). 
Most of the Bcl-2 family members contain a transmembrane domain at their COOH-terminus, 
which is important for their targeting to intracellular membranes. Anti- and pro-apoptotic Bcl-
2 proteins can be found in the cytosol, endoplasmic reticulum, mitochondria and nuclear 
envelope (137-139). The pro-apoptotic activity of Bcl-2 proteins is regulated by transcription 
and/or posttranslational modification. For example, Noxa and Puma are under p53-mediated 
transcriptional control and are upregulated in response to DNA-damage (140). 
Phosphorylated Bad is sequestered by 14-3-3 proteins under normal conditions, and growth 
factor deprivation leads to Bad dephosphorylation and activation (141). Bib is subjected to 
proteolytic cleavage by caspase-8, granzymeB or calpain and truncated Bid (tBid) translocates 
to the mitochondria, resulting in energetic failure and release of pro-apoptotic factors (142-
144). The pro-apoptotic Bcl-2 protein Bax is localized under normal conditions in the cytosol. 
In response to death stimuli Bax undergoes a conformational change that triggers its 
translocation to and insertion into the outer mitochondrial membrane. This leads to 
permeabilization of the mitochondrial membrane and release of pro-apoptotic proteins. Bax 
function has been reported to be directly inhibited by Bcl-XL and Mcl-1 (145). In contrast Bak 
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is always localized in the mitochondrial membrane as an integral protein and is maintained in 
an inactive conformation by anti-apoptotic Bcl-2 family proteins or by the type2 voltage-
dependent anion channel (VDAC) (146, 147).  
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Figure 4: Intrinsic and extrinsic apoptotic pathways.  
The death receptor pathway is triggered by members of the death receptor superfamily such as Fas and TNFRI. 
Binding of Fas-ligand (FasL) to Fas induces receptor clustering and formation of a death inducing signalling 
complex (DISC). This complex recruits, via the adaptor molecule FADD, multiple pro-caspase-8 molecules, 
resulting in caspase-8 activation through induced proximity. The intrinsic (mitochondrial) pathway is activated 
in response to different stimuli, such as DNA-damage and cytokine deprivation and leads to activation of pro-
apoptotic members of the Bcl-2 family. Apoptotic signals activate the Bcl-2 proteins through proteolysis, 
dephosphorylation and several other mechanisms and target them to the mitochondria where they induce 
cytochchrome c release. 
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2 Aim of this study 
 
The soluble form of the IL-6R is generated by alternative splicing or by limited proteolysis 
(shedding). Importantly, elevated levels of soluble IL-6R were detected in body fluids of 
rheumatoid arthritis, multiple myeloma and Crohn’s disease patients. Ectodomain shedding of 
the IL-6R can occur in a constitutive fashion mediated by ADAM10 activity or can be 
stimulated. Although the major protease, which is involved in stimulated IL-6R shedding was 
identified as ADAM17 (TACE), little is known about the physiological stimuli leading to 
generation of the sIL-6R during normal and pathological conditions. Unphysiologic activators 
of IL-6R ectodomain shedding are phorbol ester and cholesterol depleting agents, such as 
methyl-β-cyclodextrin.  
The aim of this study was to identify physiologic stimuli leading to IL-6R shedding. 
Comparison of already described stimuli leading to generation of sIL-6R, like bacterial toxins, 
PKC activation and translocation to the plasma membrane, cholesterol depletion, and CRP-
treatment, revealed that all of them trigger membrane alterations or perturbation. During 
apoptosis drastic membrane changes occure when phosphatidylserine is exposed to the 
exterior of the plasma membrane. Therefore it was reasonably to argue that apoptosis-induced 
membrane alterations might also lead to an induction of ectodomain shedding of the IL-6R. 
To investigate if apoptosis is a natural stimulus of IL-6R shedding, intrinsic apoptotic 
pathways were induced in Ba/F3 [gp130/IL-6R] cells by doxorubicin treatment or cytokine 
deprivation. Moreover, extrinsic apoptosis was induced in the hepatocellular cell line HepG2 
by Fas ligation. Studies on human neutrophils, which have been shown to express the IL-6R, 
should clarify if apoptosis-induced IL-6R shedding is promoted on primary cells and if the 
sIL-6R generated during programmed cell death facilitates IL-6 trans-signalling in vivo.  
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3 Material and Methods 
 
3.1 Material 
 
3.1.1 Chemicals 
 
All chemicals were obtained from the following companies in p.a. quality:  
 
Company Chemicals 
CarlRoth (Karlsruhe, Germany),  
Sigma-Aldrich (Deisenhofen, Germany),  
Merck (Darmstadt, Germany) 
Serva (Heidelberg, Germany) 
 
buffer components 
Sigma-Aldrich (Deisenhofen, Germany) Doxorubicin, diphenyleneiodonium chloride (DPI, NADPH- 
oxidase inhibitor), GF10920X (pan-PKC inhibitor), Gö6976 
(Ca2+-dependent PKC inhibitor), cycloheximide, streptavidin 
coupled-agarose beads, SB202190 (p38-MAPK inhibitor), 
U0126 (Erk-MAPK inhibitor), 1,3-dimethyl-2-thiourea 
(DMTU, ROS-scavenger ) and n-propyl-gallete (nPG, ROS-
scavenger) 
 
Calbiochem (Schwalbach am Taunus, 
Germany) 
 
TAPI-2 (metalloprotease inhibitor), PMA, z-LEHD-FMK 
(caspase-9 inhibitor) 
Bachem (Weil am Rein, Germany) z-VAD-FMK (pan-caspase inhibitor), z-DEDV-FMK 
(caspase-3 inhibitor), z-IETD-FMK (caspase-8 inhibitor) 
 
Glaxo-Smith Kline (Stevenage, United 
Kingdom) 
GI254023X (ADAM10-inhibitor), GW280264X (ADAM10 
and ADAM17 inhibitor), marimastat (metalloprotease 
inhibitor) 
 
 
Restriction enzymes, molecular weight markers, Taq-polymerase, Pfu-Polymerase, T4-DNA-
Ligase, Calf Intestine Alkaline Phosphatase (CIAP) and Reverse Transcriptase were obtained 
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from MBI Fermentas (St. Leon-Rot, Germany). Oligonucleotides were ordered from 
Metabion (München, Germany). All oligonucleotides used are listed in the appendix. Cell 
culture material was ordered from Sarstedt (Nürnbrecht, Germany). Cell culture media, 
Trypsin, FCS, L-glutamin and Penicillin/Streptomycin were obtained from PAA Laboratories 
(Pasching, Austria). 
 
3.1.2 Solutions and buffers 
 
Annexin V-binding buffer 10 mM  HEPES, pH 7.4 
(FACS)   140 mM  NaCl 
    2.5 mM  CaCl2 
    0.05 % (w/v) Na3Na 
 
 
Blocking buffer  6 %  milk powder or BSA in TBS-T 
(Western blot) 
 
 
Blotting buffer  25 mM  Tris-HCl, pH 8.3  
(Western blot)   192 mM  glycine 
    20 % (v/v) methanol 
 
 
DNA-sample buffer (5x) 20 % (w/v) glycerol in TBE buffer 
(DNA-gels)   0.025 % (w/v) bromphenol blue 
 
 
Destaining solution  10 % (v/v) acetic acid 
(protein gels)   40 % (v/v) methanol 
 
 
Elution buffer   0.5 M  glycine, pH 3.0 
(antibody  
purification) 
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FACS buffer   1 % (w/v) BSA in PBS 
(FACS)   0.05 % (w/v) Na3Na 
 
 
Hypotonic lysis buffer 42 mM  KCl 
(cell lysis)   10 mM  HEPES pH 7.4 
    5 mM  MgCl2 
    1 x  protease inhibitors 
 
 
Lysis buffer   150 mM  NaCl 
(cell lysis)   2 mM  EDTA 
    50 mM  Tris-HCl, pH 7.4 
    1 % (w/v) Triton X-100 
    1 % (w/v) NP-40 
    1 mM  Na3VO4 
    1 mM  NaF 
    1 x  protease inhibitors 
 
 
Neutralizing buffer  1 M  Tris-HCl, pH 11 
(antibody  
purification) 
 
 
Phosphate buffered saline  150 mM  NaCl 
(PBS)    8 mM  Na2HPO4, pH 7.4 
    1.7 mM  NaH2PO4, pH 7.4 
 
 
PBS-T    0.05 % (v/v) Tween-20 in PBS 
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Protease-inhibitors  COMPLETETM pills, Roche (Mannheim, Germany).  
Resuspending 1 pill in 2 ml PBS results in a 25x stock 
    solution 
 
 
Running gel 10 % (8 %) 7.74 ml (4.5 ml) deionized water 
(protein gels)   5.1 ml (5.1 ml) 1.5 M Tris, pH 8.8 
    0.2 ml (0.2 ml) 10 %SDS 
    6.6 ml (9.9 ml) 30 % Acrylamide-Bis 29:1 
    200 µl (200 µl) 10 % APS 
    20 µl (20 µl) TEMED 
 
 
S1 Buffer    50 mM  Tris-HCl, pH 8.0 
(Miniprep)   10 mM  EDTA 
    100 µg/ml  RNaseA 
 
 
S2 Buffer   200 mM  NaOH 
(Miniprep)   1 %  SDS 
 
 
S3 Buffer    2.8 M  KAc, pH 5.1 
(Miniprep)     
 
 
Sample-buffer (5X)  10 % (w/v) SDS 
(protein-gels)   5 % (w/v) β-mercaptoethanol 
    50 % (w/v) glycerol 
    0.13 % (w/v) bromphenol blue 
    312 mM  Tris-HCl, pH 6.8 
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Sample-buffer (2x)  4 % (w/v) SDS 
(protein-gels)   20 % (w/v) glycerol 
    5 % (v/v) β-mercaptoethanol 
    0.13 % (w/v) bromphenol blue 
    125 mM  Tris-HCl, pH 6.8 
 
 
SDS running buffer  25 mM  Tris-HCl, pH 8.3 
(protein-gels)   192 mM  glycine 
    0.1 % (w/v) SDS 
 
 
Stacking gel (4 %)  3.72 ml  deionized water 
(protein gels)   0.625 ml  0.5 M Tris-HCl, pH 6.8 
    0.05 ml  10 % SDS 
    0.67 ml  30 % Acrylamid-Bis 29:1 
    25 µl  10 % APS 
    7 µl  TEMED 
 
 
Coomassie staining solution 40 % (v/v) ethanol 
(protein gels)   10 % (v/v) acetic acid 
    0.1 % (w/v) coomassie R250 
 
 
Sripping solution  0.5 M  NaCl 
(Western blot)   0.5 M  acetic acid 
 
 
TBE (0.5x)   44.5 mM  boric-acid 
(agarose-gels)   10 mM  EDTA, pH 8.0 
    44.5 mM  Tris-HCl 
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Tris buffered saline  10 mM  Tris-HCl, pH 8.0 
(TBS)    150 mM  NaCl 
 
 
TBS-T    1 % (v/v) Tween-20 in TBS 
 
3.1.3 Bacterial media 
 
LB-medium   10 g/l  Bacto-tryptone 
 
    10 g/l  NaCl 
 
    5 g/l  yeast extract 
 
 
LB-agar   20 g/l  agar in LB-medium 
 
 
Media were autoclaved and 100 mg/l ampicillin or 25 mg/l kanamycin were supplemented 
prior to use. 
 
3.1.4 Bacterial strains and cell lines 
 
Ba/F3     murine peripheral blood pre-B-cell line (IL-3 dependent) 
 
Ba/F3 [gp130] murine pre-B-cell line stably transfected with the human cDNA 
encoding gp130 (IL-3 or HIL-6 dependent) (148) 
 
Ba/F3 [gp130/IL-6R] murine pre-B-cell line stably transfected with the human cDNAs 
encoding gp130 and IL-6R (IL-3 or IL-6 dependent) (149) 
 
HepG2   human hepatocellular carcinoma cell line 
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COS-7 African green monkey (Cercopithecus aethiops) kidney 
fibroblast-like cell line transformed with an origin defective 
mutant of SV40 which codes for wild type T antigen 
 
Hybridoma [4-11] fusion cell line of primary murine B-cells with the murine 
myelom cell line P3X63-Ag 8 635 
 
Hybridoma [14-18] fusion cell line of primary murine B-cells with the murine 
myelom cell line P3X63-Ag 8 635 
 
Escherichia coli XL1-Blue Stratagene 
 
Escherichia coli DH5α Stratagene 
 
3.1.5 Cell culture growth media 
 
Ba/F 3 [gp130]  Dulbecco MEM (DMEM), high glucose (4.5g/l) 
medium   supplemented with 
    10 % (v/v) fetal calf serum (FCS) 
    50 U/ml penicilline/streptomycine 
    10 ng/ml recombinant HIL-6 
 
 
Ba/F 3 [gp130/IL-6R]  Dulbecco MEM (DMEM), high glucose (4.5g/l) 
medium   supplemented with 
    10 % (v/v) fetal calf serum (FCS) 
    50 U/ml penicilline/streptomycine 
    10 ng/ml recombinant human IL-6 
 
HepG2/COS-7  Dulbecco MEM (DMEM), high glucose (4.5g/l) 
medium   supplemented with 
    10 % (v/v) fetal calf serum (FCS) 
    50 U/ml penicilline/streptomycine 
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Hybridoma [4-11]/[14-18] RPMI 1640 
medium   supplemented with 
    10 %(v/v) fetal calf serum (FCS) 
    200 mM L-glutamin 
    50 U/ml penicilline/streptomycin 
    0.07 % β-mercaptoethanol  
    10 %  conditioned J774-supernatant 
 
 
Blood peripheral  RPMI 1640 
granulocyte   supplemented with 
medium   10 % (v/v) fetal calf serum (FCS) 
    200 mM L-glutamine 
    50 µM  β-mercaptoethanol 
100 mM HEPES 
    50 U/ml penicilline/streptomycin 
 
3.1.6 Molecular weight markers 
 
1kb DNA ladder  14 bands within the range from 150-10,000 bp 
    (MBI Fermentas) 
 
Protein ladder 5 µl of the Prestained Protein Molecular Weight Marker (MBI 
Fermentas) were loaded on the SDS-PAGE gel. 5 bands within 
the range from 25-180 kDa 
 
3.1.7 Plasmids 
 
pESK   Donor vector (Gateway system); kanamycin-resistance  
 
 
p409b   Mammalian expression vector for transfection; ampicilline-resistance 
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pEGFP-N1 Mammalian expression plasmid encoding for the enhanced green 
fluorescent protein; kanamycin-resistance (Clontech) 
 
3.1.8 Primary Antibodies 
 
anti-c-myc mouse monoclonal antibody clone 9E10. Raised against the epitope 
EQKLISEEDLN. 
   Application: 
IB: 10 % conditioned hybridoma supernatant (6 % milk powder in 
TBS) 
 
 
anti-TACE rabbit polyclonal antibody derived from a peptide consisting of the C-
terminus of TACE (Chemicon). 
   Application: 
   IB: dilution 1:5,000 (6 % milk powder in TBS) 
 
 
anti-IL-6R (6.2) rabbit polyclonal antibody recognizing the extracellular stalk-region of 
the human IL-6R (150). 
   Application: 
   IP: dilution 1:1,000 (6 % milk powder in TBS) 
 
 
anti-IL-6R (M-91) mouse monoclonal antibody raised against the extracellular part of the 
human IL-6R (Immunotech). 
   Application: 
   FACS: dilution 1:500 (FACS-buffer) 
 
 
anti-IL-6R (14-18) mouse monoclonal antibody raised against the extracellular part of the 
human IL-6R (this work). 
   Application: 
   IB: dilution 1:5,000 (6 % milk powder in TBS) 
Material and Methods 
 
  27 
 
anti-caspase-3 rabbit polyclonal antibody raised against the residues surrounding the 
cleavage site of human caspase-3 (Cell signalling). 
   Application: 
   IB: dilution 1:2,000 (6 % milk powder in TBS-T) 
 
 
anti-PARP: rabbit monoclonal antibody which detects full-length PARP and the 
large fragment (89 kDa) produced by caspase cleavage (Cell 
signalling). 
   Application: 
   IB: dilution 1:2,000 (6 % milk powder in TBS-T) 
 
 
anti-PKCδ (C-20) rabbit polyclonal antibody raised against the C-terminus of human 
PKCδ (Santa Cruz). 
   Application: 
   IB: dilution 1:1,000 (6 % milk powder in TBS) 
 
 
anti-β-actin  mouse monoclonal antibody raised against the N-terminus of β-actin 
(AC-15):  (abCAM). 
   Application: 
   IB: dilution 1:5,000 (6 % milk powder in TBS) 
 
 
anti-STAT3: mouse monoclonal antibody which detects endogenous levels of total 
STAT3 protein (Cell Signalling). 
   Application:  
IB: 1:2,000 (6 % milk powder in TBS-T) 
 
 
 
 
Material and Methods 
 
  28 
 
anti-Phospho-  rabbit monoclonal antibody which detects endogenous levels of STAT3 
STAT3  only when phosphoryated at tyrosine 705 (Cell signalling). 
   Application:  
IB: 1:2,000 (6 % BSA in TBS-T) 
 
 
anti-Fas:  mouse monoclonal antibody (IgM) recognizing the human cell surface 
(CH-11)  antigen Fas (Upstate). 
   Application: 
   Induction of apoptosis in HepG2 cells (25-100 ng/ml) 
 
 
anti-mIL-6R: rat monoclonal antibody raised against the extracellular part of the  
(D7715A7) murine IL-6R (Biozol). 
   Application: 
In vivo receptor blocking: 100 µg were injected intraperitoneally (i.p.) 
in C57Bl/6 mice 
 
 
anti-mIL-6R: rat anti-mouse monoclonal antibody raised against the extracellular  
(MR-16-1) part of the murine IL-6R (Shugai pharmazeutical, kindly provided by 
Dr. M. Neurath). 
   Application: 
In vivo receptor blocking: 100 µg were injected intraperitoneally (i.p.) 
in C57Bl/6 mice 
 
 
anti-Ly6G/Ly6C-: rat monoclonal antibody which reacts with a common epitope on Ly-6G  
FITC and Ly-6C, previously known as the myeloid differentiation antigen Gr-
1. The antibody recognizes granulocytes (neutrophils and eosinophils) 
and monocytes (BD Pharmingen). 
   Application: 
   FACS: 1:400 (FACS-buffer) 
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anti-F4/80-APC: rat monoclonal antibody which reacts with the mouse F4/80 antigen, a 
macrophage-restricted cell surface glycoprotein (CALTAG 
Laboratories/Invitrogen). 
   Application: 
   FACS: 1:400 (FACS-buffer)    
 
3.1.9 Secondary antibody 
 
All horseradish-coupled secondary antibodies were purchased from Amersham Bioscience 
(Buckinghamshire, United Kingdom) and used in a dilution of 1:10,000.  
For fluorescence-activated cell sorting (FACS) analysis, the allophycocyanin-conjugated 
secondary antibody was obtained from Jackson Immuno Research Laboratories/Dianova 
(Hamburg, Germany) and used in a dilution of 1:100. 
 
3.1.10 Recombinant cytokines 
 
human IL-6 prepared and purified as described in (151). 
 
 
Hyper-IL-6 The fusion protein of the human IL-6 and the human IL-6R, Hyper-IL-6 ; 
prepared and purified as described in (152). 
 
 
sgp130-Fc kindly provided by Steffi Schnell (Biochemical Department, University of 
Kiel); was prepared and purified as described in (73). 
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3.2 Methods 
 
3.2.1 Molecular biology 
 
3.2.1.1 Transformation of bacteria 
 
To 100 µl competent E.coli XL1-Blue or DH5α either 50-100 ng of plasmid DNA or 20 µl of 
ligation mixture were added and incubated for 3 min on ice. After a heat shock (1 min, 42°C) 
an successive incubation on ice (3 min), 800 µl of LB-medium were added to the bacteria and  
incubated at 37°C for 60 min. Cells were then centrifuged (6,000 x g, 1 min) and the 
supernatant removed. Cells were resuspendet in 100 µl LB-medium and plated on LB-agar 
plates containing the appropriate antibiotics. Plates were incubated at 37°C overnight. 
 
3.2.1.2 Plasmid isolation from 2 ml E. coli cultures (Minipreps, (153)) 
 
2 ml LB-medium supplemented with the appropriate antibiotic was inoculated with a single 
colony and incubated over night at 37°C with constant agitation. Cultures were pelleted by 
centrifugation (6,000 x g, 1 min) and resuspended in 100 µl Buffer S1. For bacterial lysis the 
suspension was supplemented with 100 µl Buffer S2 and incubated for 2-3 min at room 
temperature. Subsequent 100 µl of Buffer S3 was added and the mixture was inverted until a 
homogenous suspension containing a white flocculate was formed. The bacterial lysate was 
cleared by centrifugation (16,000 x g, 15 min, and 4°C) and the resulting supernatant was 
transferred to a new reaction tube and supplemented with 900 µl ice cold 100 % ethanol. 
After an incubation time of 30 min at -20°C the plasmid DNA was precipitated by 
centrifugation (16,000 x g, 15 min, 4°C) and washed once with ice cold 70 % ethanol. The 
DNA pellet was dried at room temperature for 30 min at 50°C and dissolved in 50 µl Tris-
HCl (10 mM, pH 8.0). 
 
3.2.1.3 Plasmid isolation from 100 ml E. coli cultures (Midiprep) 
 
For preparation of large quantities of DNA, the Macherey-Nagel Nucleo Bond Midiprep kit 
was used. A single colony was inoculated in 2 ml LB-medium and grown at 37°C for 8 hours 
with constant agitation. Afterwards, this culture was added to 100 ml LB-medium 
supplemented with the appropriate antibiotic and incubated at 37°C with constant agitation 
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over night. The culture was transferred into a 50 ml Falcon tube and the cells were pelleted by 
centrifugation (4,000 x g, 15 min, 4°C). The plasmid was isolated from the bacteria according 
to the manufactures protocol. Finally the DNA pellet was resuspended in 200 µl Tris-HCl (10 
mM, pH 8.0) and the DNA concentration was determined. 
 
3.2.1.4 Digestion of DNA (153) 
 
For restriction, the DNA was incubated with an appropriate amount of restriction enzymes in 
the recommended buffer for 2-3 hours at 37°C. Restriction was terminated by addition of 
DNA sample buffer and applied on a agarose gel. If two enzymes were incompatible with 
each other, the DNA was digested successively with the enzymes. The DNA was purified 
between the two digestions using the PCR purification kit (Qiagen). 
 
3.2.1.5 Dephosphorylation of Plasmid-DNA (154) 
 
After enzymatic restriction the plasmid-DNA was dephosphorylated by directly addition of 1 
U Calf Intestinal Alkaline Phosphatase (CIAP) to the restriction reaction. The 
dephosphorylation was carried out at 37 °C for 60 min. 
 
3.2.1.6 Ligation of DNA-fragments 
 
Ligation of DNA fragments was performed by mixing 50 ng vector with the five-fold molar 
excess of insert DNA. The DNA fragments were supplemented with 1 µl T4-ligase (MBI, 
Fermentas), 2 µl ligation buffer (10x) and were filled up to a final volume of 20 µl. The 
reaction was incubated for 1 hour at room temperature and was used directly for 
transformation in competent E.coli bacteria. 
 
3.2.1.7 Polymerase chain reaction (PCR) 
 
For amplification of the DNA fragment encoding the dominant negative variant of ADAM17 
the PCR was performed in a 50 µl reaction mix in Stratagene PCR-cycler (Robocycler 
Gradient 96). The enzymes Taq-polymerase as well as Pfu-Polymerase and the appropriate 
buffers were obtained from MBI Fermentas. The following reaction mixture was used : 
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Template   2-10 ng 
Forward-primer  10 pmol (appendix) 
Reverse-primer  10 pmol (appendix) 
Nucleotides (dNTPs)  10 mM each 
PCR-buffer (10x)  5 µl 
Pfu/Taq-polymerase  1 U 
ddH2O    add 50 µl 
 
The PCR was performed with the following step gradient : 
 
95°C  2 min   initial denaturation step 
95°C  30 sec   denaturation  
50°C  30 sec      x35  primer annealing 
72°C  1 min   elongation (1 min/1kb) 
72°C  5 min   final elongation step  
 
3.2.1.8 RT-PCR 
 
RT-PCR is a PCR amplification of a product from the reverse transcription (RT) reaction, 
whereby a template mRNA is translated into a single-stranded cDNA. RevertAid M-MuLV 
Reverse Transcriptase from Fermentas was employed according to the manufacturer`s 
instructions. The reactions were performed using oligo(dT) primer targeting the 3’ poly(A) 
mRNA tail. The PCR settings were described above. The following reaction mixture was 
used: 
 
RNA    2 µg 
Oligo (dT)   0.5 µg 
ddH2O    5 µl 
 
 
The mixture was heated at 70°C for 5 min and then chilled on ice. The following components 
were added: 
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reaction buffer (5x)  4 µl 
dNTPs    20 mM each 
RevertAid M-MuLV RT 1 µl 
ddH2O    add 20 µl 
 
The reaction mix was incubated at 37°C for 1 hour and afterwards the Reverse Transkriptase 
was heat inactivated at 75°C for 15 min. 2 µl of the resulting cDNA was used directly for the 
subsequent PCR. 
 
3.2.1.9 DNA Gel-electrophoresis 
 
DNA fragments were separated by horizontal electrophoresis cambers (BioRad) using agarose 
gels. Agarose gels were prepared by heating 1-2 % (w/v) agarose (Biozym) in 0.5 x TBE 
buffer, depending on the size of the DNA fragments, and the gels were supplemented with 
0.05 % ethidium bromide. The samples were mixed with an appropriate amount of 6 x DNA 
sample buffer and loaded on the agarose gel. The gels were run at constant voltage (100 V) 
and finally documented using the Gel Doc 2000 UV-light documentation system (BioRad). 
 
3.2.1.10 Extraction of DNA fragments from agarose gels 
 
For isolation and purification of DNA fragments from agarose gels, ethidium bromide-stained 
gels were illuminated with UV-light and the appropriate DNA band was excised from the gel 
with a clean scalpel and transferred into a reaction tube. The fragment was isolated by using 
the QIAquick Gel Extraction Kit (Qiagen) following the manufacturer`s instructions. 
 
3.2.1.11 Purification of DNA fragments 
 
For purification of DNA fragments, the QIAquick PCR Purification Kit (Qiagen) was used 
according to the manufactures protocol. 
 
3.2.1.12 Determination of DNA concentration 
 
DNA concentration was determined spectroscopically using an Amersham-Pharmacia 
spectrometer. The absolute volume necessary for measurement was 50 µl. Concentration was 
determined by measuring the absorbance at 260 nm, 280 nm and 320 nm. Absorbance at 260 
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nm had to be higher than 0.1 but less then 0.7 for reliable determinations. A ratio of A260/A280 
between 1.8 and 2 monitored a sufficient purity of the DNA preparation. 
 
3.2.1.13 DNA sequencing 
 
DNA sequencing was performed by the company SeqLab, Göttingen. For preparation 0.7 µg 
of DNA and 20 pmol sequencing primer were diluted in 7 µl H2O. 
 
3.2.1.14 RNA Isolation 
 
Total RNA from HepG2 cells (5 x 106 cells) was isolated with the NucleoSpin RNA II Kit 
(Macherey-Nagel) and the RNA concentration was determined by UV-spectrophotometry. 
The isolated RNA was used as template for the RT-PCR reaction were 2 µg of RNA was 
reverse transcribed in single stranded cDNA (3.2.1.7). 
 
3.2.2 Protein-biochemical methods 
 
3.2.2.1 SDS-polyacrylamide gel electrophoresis (155) 
 
Separation of proteins was performed with a discontinuous SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Mini-Protean III system (BioRad). The size of the 
running and stacking gel was as follows: 
 
Running gel:  height 4.5 cm, thickness 1.5 mm 
   10 % or 15 % acrylamid solution 
 
Stacking gel:  height 1 cm, thickness 1.5 mm 
   5 % acrylamid solution 
   15 or 10-well combs 
 
After complete polymerization of the gel, the chamber was assembled as described by the 
manufactures protocol. Up to 30 µl sample were loaded in the pockets and the gel was run at 
constant 80 V for 15 min and then at 140 V for the remainder. The gel run was stopped when 
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the bromphenol blue line reached the end of the gel. Gels were then either stained or subjected 
to Western blotting. 
3.2.2.2 Coomassie-staining of polyacrylamide gels  
 
After SDS-PAGE, the gels were stained in coomassie staining solution (30 min, RT) with 
constant agitation. The gels were then incubated in destaining solution until the backround of 
the gel appeared nearly transparent. 
 
3.2.2.3 Western Blot analysis 
 
Proteins were transferred from the SDS-gel on a PVDF membrane (Amersham-Biosciences, 
Buckinghamshire, U.K.) using a MINI TRANSBLOT-apparatus (BioRad). The blotting 
sandwich was assembled as described in the manufactures protocol. Proteins were transferred 
electrophoretically at 4°C in Blotting-buffer at constant voltage (90 V, 120 min). 
 
3.2.2.4 Immunocheminal detection of proteins on PVDF membranes  
 
After electrophoretic transfer, the membranes were removed from the sandwiches and placed 
with the protein-binding side up in plastic vessels. Membranes were immediately incubated 
with 20 ml blocking buffer for 1 hour at RT or overnight at 4°C. Afterwards, the primary 
antibody was added in the appropriate dilution either for 4 hours at RT or overnight at 4°C. 
The primary antibody was removed by washing the membrane 3 x 10 min with TBS-T. The 
appropriate secondary antibody was applied for 1 hour at RT and afterwards the membrane 
was washed again 6 x 10 min with TBS-T. Immunoreactive bands were visualized using the 
enhanced chemiluminescence detection system (Amersham-Biosciences, Buckinghamshire, 
U.K.). Therefore the membrane was soaked for 1 min in detection solution and afterwards 
placed between to transparent foils. The membrane was exposed to X-ray film (Amersham-
Biosciences, Buckinghamshire, U.K.) or with the chemilumiseszense kamara system LAS-
1000 (Fujifilm, USA) for defined time periods. 
 
3.2.2.5 Densidometric evaluation of band intensity 
 
Densidometric evaluation of protein-band intensities was performed with digitized pictures. 
Band densities were quantified using the image processing sogtware ImageJ (National 
Institute of Health, USA). 
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3.2.2.6 Determination of protein concentration (BCA) 
 
The protein concentration of cell lysates was determined using the BCA kit (Pierce). Solution 
A and B were mixed (ratio 1:50) to give the BCA solution. 10 µl of the cell lysate were mixed 
with 200 µl BCA solution in microtiter plates and incubated for 30 min at 37°C. A BSA 
standard curve was co-incubated ranging from 3,000 µg/ml to 46 µg/ml. The extinction of the 
samples was determined at 568 nm in a microtiter plate reader (Tecan, Maennedorf, 
Switzerland).  
 
3.2.3 Cell culture 
 
3.2.3.1 Cultivation and transient transfection of the adherend cell line HepG2 
 
HepG2 cells were obtained from the American Type Culture Collection (Rockville, 
MD/Manassa, VA) and were cultivated at 37°C, 5 % CO2 and 90 % relative humidity in 
dishes (10 cm diameter) with 10 ml culture medium. Cells were passaged when they were 
confluent (usually after 3-4 days). Medium was removed and cells were detached by 
incubation with 3 ml Trypsin/EDTA (PAA Laboratories) for 5 min at 37°C. Cells were 
centrifuged (1,000 x g) and the pellet was resuspended in 10 ml fresh medium. Cells were 
split 1:10 for maintenance or seeded in dishes (10 cm diameter, 3 x 106 cells) for transfection.  
HepG2 cells were transfected using DEAE-Dextran. Before transfection, the culture medium 
was replaced to 75 µM chloroquin-containing culture medium. For one 1 culture dish (10 cm 
diameter), 5 µg of the appropriate plasmid DNA was thoroughly mixed with 435 µl 
Chloroquin-containing medium and 65 µl DEAE-Dextran (4 mg/ml). The mixture was 
dropwise added to the cells followed by 4-6 hours incubation at 37°C. Then the culture 
medium was removed and the cells were treated with medium containing 10 % DMSO for 7 
min at room temperature. Subsequently the cells were washed with PBS and new medium 
was added. The next day, the medium was exchanged again. 
 
3.2.3.2 Cultivation of suspension cell lines 
 
Ba/F3 and hybridoma cells were grown continuously in suspension culture and were 
maintained at 37°C, 5 % CO2 and 90 % relative humidity in dishes (10 cm diameter) with 10 
ml culture medium. For subcultivation the cells were spun down (800 x g, 5 min, RT) and the 
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resulting cell pellet was resuspended in 10 ml fresh medium. Ba/F3 cells were split 1:100 
whereas the Hybridoma cells were split 1:10 for maintenance. 
For production of the human IL-6R antibodies 4-11 and 14-18, the hybridoma cells were 
seeded in dishes (10 cm diameter) at a density of 1 x 106 cells/ml Hybridoma Express medium 
(PAA Laboratories) supplemented with 2 mM L-glutamin. After 5 days the cells were spun 
down (3,000 x g, 30 min, 4°C), the supernatant containing the produced antibodies was 
transferred into a new collection tube and was finally stored at -80°C. 
 
3.2.3.3 Cell lysis  
 
After stimulation of HepG2 cells, the culture medium was removed and the cells were washed 
twice with ice cold PBS and placed on ice. Cells were scraped of the wells, transferred into a 
1.5 ml eppendorf tube and resuspendend in chilled lysis buffer (100 µl lysis buffer/0.5 x 106 
cells). Cells were lysed for 1 hour at 4°C with constant agitation. Debris was removed by 
centrifugation (16,000 x g, 15 min, 4°C) and the supernatant was stored at -20°C. 
Suspension cells were spun down (1,000 x g, 5 min RT) and the resulting cell pellet was 
washed twice with ice cold PBS before resuspension in lysis buffer (100 µl lysis buffer/1 x 
106 cells). 
 
3.2.3.4 Surface biotinylation of transfected HepG2 cells 
 
48 hours after transfection, HepG2 cells were washed twice with ice cold PBS and placed on 
ice. Surface proteins were biotinylated by incubating the cells with 0.1 mg/ml Sulfo-NHS-LC-
biotin (Pierce, Rockford, IL, USA) in PBS for 30 min at 4°C. Biotinylation was terminated by 
addition of a 20 mM glycine solution in PBS for 10 min at 4°C. Afterwards the cells were 
washed 5 times with ice cold PBS and finally scraped of the wells, transferred into a 1.5 ml 
eppendorf tube and resuspendend in chilled lysis buffer (100 µl lysis buffer/0.5 x 106 cells). 
Cells were lysed for 1 hour at 4°C with constant agitation. Debris was removed by 
centrifugation (16,000 x g, 15 min, 4°C) and the supernatant was diluted 1:5 with PBS. 
Biotinylated surface localized proteins were precipitated with 30 µl streptavidin-coupled 
agarose beads (Sigma-Aldrich, Deisenhofen, Germany) at 4°C overnight with constant 
agitation. Agarose beads were pelleted by centrifugation (1,800 x g) and washed twice with 
PBS. Precipitated proteins were solubilised by addition of 60 µl SDS-sample buffer (2 x) to 
the agarose beads. Proteins were separated by SDS-PAGE for further Western blot analysis 
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3.2.3.5 Preparation of cytosolic and membrane fractions 
 
48 hours after transfection 5 x 106 HepG2 cells were washed twice with ice cold PBS, scraped 
of the wells and resuspended in 300 µl hypotonic lysis buffer for 60 min at 4°C. Afterwards 
the cell suspension was passaged several times through a 22-gauge needle and centrifuged 
(500 x g, 10 min, 4°C) to remove remaining cells and debris. The resulting post-nuclear 
supernatant was centrifuged again (100,000 x g, 1 h, 4°C). After centrifugation the 
supernatant represent the cytosolic fraction and was transferred into a new collection tube. 
The membrane pellet was resuspended in 100 µl lysis buffer and incubated on ice for 60 min. 
The lysate was centrifuged again (16,000 x g, 15 min, 4°C) and the resulting supernatant 
represent the membrane fraction. Both, cytosolic and membrane fractions, were stored at -
20°C. 
 
3.2.3.6 Induction of cellular apoptosis and immunoprecipitation of the sIL-6R 
 
Ba/F3 [gp130/IL-6R] cells were washed 3 times with PBS and seeded out at a density of 1 x 
106 cells/ml. Apoptosis was induced by addition of 500 ng/ml doxorubicin or cytokine 
withdrawal. 
HepG2 cells transfected with the p409-huIL-6R plasmid were seeded out 24 hours after 
transfection at a density of 3 x 105 cells/ml in a six-well plate. For induction of apoptosis, 
HepG2 cells were treated with 100 µM cycloheximide (CHX) for 120 min prior to stimulation 
with 500 ng/ml of the anti-Fas antibody (CH-11). All other inhibitors were added 30 min prior 
anti-Fas stimulation. 
Freshly isolated neutrophils were seeded out at a density of 5 x 106 cells/ml and treated with 
UV (200,000 µJ/cm2) or anti-Fas (500 ng/ml) and were incubated for 6 hours at 37°C.  
After induction of apoptosis the supernatant was removed and centrifuged for 5 min at 16,000 
x g at 4°C to remove cell debris. The cleared supernatant was transferred into a new collection 
tube and supplemented with 2 µl of the polyclonal IL-6R antiserum 6.2 (150) and 30 µl of 
protein A-coupled agarose beads (Amersham-Biosciences Buckinghamshire, U.K.). The sIL-
6R was precipitated over night under constant agitation at 4°C and afterwards the beads were 
washed twice with PBS. Proteins were eluted from the beads with 2x SDS sample buffer (10 
min, 95°C) 
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3.2.3.7 Isolation of human peripheral blood granulocytes (PMNs) 
 
Peripheral blood was collected by venipuncture from healthy adult volunteers. Approval was 
obtained from the University Hospital Schleswig-Holstein institutional review board for these 
studies. Informed consent was provided according to the Declaration of Helsinki. 5 ml 
anticoagulated blood (lithium heparin) was layered onto a histopaque gradient consisting of 
two layers: 2 ml lymphocyte separation medium (PAA Laboratories, Pasching, Austria) on 
the top and 5 ml histopaque 1119 (Sigma-Aldrich, Deisenhofen, Germany) at the bottom prior 
to centrifugation at 800 x g for 20 min at room temperature. The granulocyte rich layer of 
histopaque 1119 was collected and washed once in PBS. The PMN pellet was resuspendet in 
2 ml RPMI 1640 medium and further fractionated on a discontinuous percoll (Amersham-
Biosciences Buckinghamshire, U.K.) gradient consisting of layers, 2 ml each, with densities 
of 1.105 g/ml (85 %), 1.100 g/ml (80 %), 1.093 g/ml (75 %), 1.087 g/ml (70 %), 1.081 g/ml 
(65 %) percoll. After centrifugation for 20 min at 800 x g, the interface between the 80 % and 
85 % percoll layers was collected and washed twice in PBS. PMN purity was more than 95 % 
as assessed by size and granularity on flow cytometry.  
Isolated PMNs were counted with a Neubauer cell-counter chamber and seeded out at a 
density of 5 x 106 cells/ml in RPMI 1640 medium (3.1.5) prior stimulation. 
 
3.2.4 Enzyme-linked immunosorbent assay (ELISA) 
 
1. To determine the concentration of different antigens the two antibody “sandwich” 
ELISA method was used. First, the capture antibody was coated to a microtitre plate (Greiner 
Microlon, Solingen, Germany). After blocking, antigen is added and allowed to complex with 
the bound antibody. Unbound products were removed by extensive washing, and a 
biotinylated detection antibody was added. Finally subsequent addition of streptavidin-
horseradish peroxidase (Roche, Mannheim, Germany) and peroxidase substrate (Roche, 
Mannheim, Germany) led to a calorimetric reaction which allowed the quantitation by 
measuring the amount of bound detection antibody. To determine the absolute amount of 
antigen in the samples a purified antigen standard was used. The following general protocol 
was used: 50 µl of coating antibody-solution was added to each well and incubated at RT over 
night; the wells were washed three times with PBS-T; 200 µl of blocking buffer was added to 
saturate the remaining protein binding sites on the microtiter plate for 2 hours at room 
temperature; the wells were washed three times with PBS-T; 50 µl of antigen solution (mostly 
conditioned supernatants) or purified antigen standard were added to each well for 2 hours at 
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RT. The samples were diluted in PBS supplemented with 1 % BSA; the wells were washed 
three times with PBS-T; 50 µl of detection antidody solution was added to each well 
incubated at RT for 2 hours; the wells were washed three times with PBS-T; 100 µl of 
streptavidin-horseradish peroxidase solution (1: 5,000 in PBS supplemented with 1 % BSA) 
was added and incubated for 45 min at RT; the wells were washed three times with PBS-T; 75 
µl of the peroxidase substrate BM blue POD (Roche) was added for approximately 20 min 
and the reaction was stopped by addition of 75 µl 1.8 M H2SO4; the wells were washed three 
times with PBS-T; Optical densities at 450 nm were measured on an ELISA plate reader (SLT 
Rainbow; Tecan, Maennedorf, Switzerland). 
 
 
Antigen Capture antibody Blocking buffer Detection antibody 
human soluble  
IL-6R 
MAB 227 (R&D-
Systems) 
Working concentration:  
1 µg/ml 
PBS 
supplemented 
with 1 % BSA 
and  5 % sucrose 
BAF 227 (R&D-
Systems) 
Working concentration: 
50 ng/ml 
 
 
The soluble gp130 ELISA kit as well as the murine IL-6 ELISA kit were purchased from 
R&D systems and were used according to the manufactures protocol. 
 
 
3.2.5 Fluorescence-activated cell sorting (FACS) 
 
3.2.5.1 Flow cytometry analysis of cell surface proteins 
 
Ba/F3 [gp130/IL-6R] cells were washed twice with FACS-buffer and then incubated with 1 
µg/ml anti-IL-6R antibody M91 for 60 min on ice. After a single wash in FACS-buffer, cells 
were incubated with the allophycocyanin-conjugated goat anti-mouse antibody for 60 min on 
ice. Cells were washed once, resuspended in 500 µl FACS buffer, and analyzed by flow 
cytometry (FACS-Canto; Becton Dickinson, Heidelberg, Germany). All centrifugation steps 
were performed at 1,000 x g for 5 min at 4°C. 
To analyze the different cell populations in the lavage fluid of carrageenan-challenged mice, 
cells were counted with a Neubauer cell-counter chamber and washed twice with FACS-
buffer. 2 x 105 cells were used for flow cytometry analysis. To block Fc-receptors on 
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neutrophils and macrophages the cell suspension was incubated for 5 min with Mouse BD Fc 
Block CD 16/32 mAB (1:500 diluted in FACS-buffer). Afterwards the cells were spun down 
(1,000 x g, 5 min, 4°C) and resuspended in FACS-buffer containing the fluorescence-coupled 
antibodies against Ly6G/Ly6C and F4/80 for 60 min on ice protected from direct light. The 
cells were subsequent washed and resuspended in 500 µl FACS-buffer and analyzed by flow 
cytometry. 
 
3.2.5.2 Flow cytometry analysis of phosphatidylserine 
 
Annexin V preferentially binds phosphatidylserine and can be used as a specific early 
indicator of apoptosis. The annexin V/propidium iodide staining kit (BD Bioscience, 
Heidelberg, Germany) was used according to the manufacturers instructions. Briefly, 3 x 105 
cells were spun down and washed twice in annexin V-binding buffer. Afterwards the cells 
were incubated in 100 µl annexin V-binding buffer containing 2 µl FITC-conjugated annexin 
V for 15 min at room temperature protected from light. Finally 400 µl annexin V-binding 
buffer was directly added to the cell suspension and the cells were analyzed within 10 min by 
flow cytometry.  
 
3.2.5.3 Flow cytomerty analysis of nucleosomal DNA fragments 
 
106 Ba/F3 [gp130/IL-6R] cells were washed twice with PBS and subsequently fixed with 
chilled 70 % methanol for at least 1 hour on ice. Afterwards the cells were washed twice with 
chilled PBS and resuspended finally in 1 ml PBS supplemented with 1 mg/ml RNase (30 min, 
37°C). After two washing steps the cell suspension was supplemented with 500 µl PBS 
containing 1 mg/ml propidium iodide incubated for 5 min at room temperature and finally 
analyzed by flow cytometry. 
 
3.2.6 Murine air pouch model of acute inflammation 
 
Animals used throughout the air pouch experiments were 8-10 weeks old male C57Bl/6 wild 
type mice and IL-6 knock-out mice (C57Bl/6 IL-6-/-) obtained from Charles River 
Laboratories (Sulzfeld, Germany). The air pouch model of local inflammation was performed 
according to Edwards et al. (156). Mice were anesthetized with ether and subcutaneous dorsal 
pouches were generated by injection of 6 ml sterile air. After three days the pouches were 
reinjected with 4 ml of air. On day 6, 1 ml of a suspension of 1 % Carrageenan (Sigma-
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Aldrich, Deisenhofen, Germany) in sterile PBS (PAA Laboratories, Pasching, Austria) was 
injected into the cavity. Carrageenan is composed of mainly sulfated polysaccharides, which 
are generally extracted from seaweed. Injection of Carrageenan into air pouches of rats and 
mice is a well established disease model of acute, local inflammation (156-158). 
Three days after Carrageenan challenge, mice were sacrificed and the pouches were washed 
with 3 ml ice-cold PBS. Exudates were collected and the volume was recorded. Total cell 
numbers were counted with a Neubauer cell-counter chamber. The remaining lavage fluid was 
centrifuged at 16,000 x g for 10 min at 4°C, and the supernatant was stored at –80°C until 
analyzed by ELISA.  
Aliquots of the exudate containing 2 x 105 cells were used for flow cytometry analysis, 
whereby the mABs Ly6GC (BD Pharmingen), F4/80 (Caltag), were employed to count 
infiltrating neutrophils and monocytes.  
 
day 0 day 3 day 6
6 ml 
sterile air
4 ml 
sterile air
1 ml 
1% carrageenan
 
 
Figure 5: Air pouch model of acute inflammation. 
Schematic representation of the air pouch time schedule. At different time points after Carrageenan injection the 
pouch was washed with 3 ml PBS and the exudate was analyzed by FACS or ELISA. 
 
 
3.2.7 Intraperitoneal injection 
 
400 µl sterile PBS or 400 µl sterile PBS containing either purified neutralizing anti-murine 
IL-6R antibody or recombinant soluble gp130-Fc were injected into the peritoneal cavity of 
an ether anesthetized mouse. Both componets were injected i.p. 6 hours before carrageenan 
challenge. Solutions were prepared and loaded under a sterile fume hood. Intraperitoneal 
injection was performed using a 1 ml syringe in combination with a 27 gauge needle. 
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3.2.8 Statistical analysis 
 
Data are expressed as mean values ± SD; 3-5 mice were used per experimental group. 
Statistical analysis was performed by using a Student’s unpaired t test 
(http://www.physics.csbsju.edu/stats/t-test.html). A p-value below 0.05 was considered 
statistically significant. 
 
3.2.9 Animal treatment 
 
Procedures involving animals and their care were conducted in conformity with national and 
international laws according to home office approved project license 66-6/06 from 9/15/2006. 
Mice were maintained in a 12 hours light-dark cycle under standard conditions and were 
provided with food and water ad libitum. All mice were maintained under barrier conditions 
and were pathogen free as assessed by regular microbiological screening. The animals were 
kept at 21°C ± 2°C and 60 % ± 5 % humidity in individually ventilated cages (IVC). 
 
3.2.10 Purification of antibodies against the extracellular part of the 
human IL-6R 
 
The murine hybridoma cell lines 4-11 and 14-18, producing monoclonal antibodies against 
the extracellular part of the human IL-6R, were generated by Hans Lange (Department of 
General and Thoracic Surgery, University Hospital Schleswig-Holstein).  
The secteted antibodies were purified from culture supernatant by affinity chromatography 
with a protein A-sepharose column (Amersham). The protein A-sepharose column was 
washed once with with 50 ml degased PBS. The antibody containing hybridoma cell culture 
supernanant (1,000 ml) was sterile filtered and degased. Afterwards the culture supernatant 
was applied to the column. This was followed by a washing step with 150 ml PBS. The bound 
antibody was eluted from the column with 20 ml elution buffer, pH 3.0 and fractions of 
approximately 1,800 µl were collected. Each fraction was neutralized by addition of 200 µl 
neutralizing buffer, pH 11. Each fractions (10 µl) was analyzed on a 15 % SDS-PAGE gel 
under reducing conditions stained with coomassie solution. The fractions which contain the 
antibody were pooled and loaded onto a NAP column (Pharmacia, Uppsala, Sweden) to 
change the buffer to PBS. Protein concentration was determined spectrophotometrically at 
280 nm. 
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4 Results 
 
4.1 Production and purification of two monoclonal antibodies, 
raised against the ectodomain of the human IL-6R 
 
BALB/c mice were immunized with recombinant human soluble IL-6R in order to obtain 
monoclonal antibodies. Immunization of mice and generation of immortalized B-cells, which 
produce large amounts of monoclonal antibodies (hybridoma cells), was performed by Hans 
Lange (Department of General and Thoracic Surgery, University Hospital Schleswig-
Holstein). The fusion of primary murine spleenocytes with the myeloma cell line P3X63-Ag 8 
635 led to generation of 57 antibody producing hybridoma cell clones. The cell culture 
supernatants, containing the secreted antibodies, were collected and antigen recognition was 
tested by Western blotting. Western blot analysis of purified Hyper-IL-6 (Figure 6A, B) and 
lysates of COS-7 cells transfected with the human IL-6R (Figure 6C) revealed that several 
clones produced antibodies which recognize the immunogen (apparent molecular size of 80 
kDa). Two cell lines (4-11 and 14-18) were selected for further studies based on their ability 
to secrete highly specific antibodies, which are able to detect the human IL-6R (Figure 6B, 
C). 
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Figure 6: Immunochemical detection of the human IL-6R with monoclonal antibodies produced by the 
hybridoma clones 4-11 and 14-18. 
A. The designer cytokine, Hyper-IL-6. Hyper-IL-6 is a fusion protein built up of human IL-6 and the human sIL-
6R connected via a flexible peptide linker (159, 160). 
B. Hyper-IL-6 (HIL-6) was subjected to SDS-PAGE and transferred to PVDF membrane after separation. The 
fusion protein was detected by the hybridoma supernatants 4-11 and 14-18 (1:500) and the anti mouse IgG-HRP 
secondary antibody (1:10,000) (* degradation product). 
C. COS-7 cells were transiently transfected with the eukaryotic expression vector p409b-IL-6R and lysed after 
48 h. The immunochemical detection of the IL-6R was performed as in Figure 6B. To exclude unspecific 
binding untransfected COS-7 cells were used as negative control. Molecular weights are present on the left. The 
mature IL-6R protein is marked by an arrow and the immature protein (probably not entire glycosylated) is 
marked by an asterisk. 
 
 
For purification of the anti-IL-6R antibodies via affinity chromatography, cell culture 
supernatants of the two hybridoma clones were harvested and collected in two independent 
pools of 500 ml each. The two pools were successively applied to a Protein A-sepharose 
column. After washing, the bound antibodies were eluted using an acidic glycine buffer. All 
eluate fractions were subjected to SDS-PAGE and stained with coomassie-blue. After 
purification two predominant bands of approximately 50 kDa and 25 kDa, representing the 
heavy and light chain of the purified antibodies, were detected in the coomassie stained gels. 
 
A. B. C.
118 kDa
85 kDa
10 101 1 HIL-6 [ng]
4-11 14-18
45 kDa
*
IL
-6
D-II
D-III
sIL-6R
Hyper-IL-6
p409b-IL-6R+- +-
4-11 14-18
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*
D-
I
Results 
 
  46 
 
Figure 7: Purification of the α-IL-6R antibodies 4-11 
and 14-18. 
1,000 ml of supernatants produced by the hybridoma 
clones 4-11 and 14-18 were applied to a Protein A-
sepharose column. The antibodies bound to the column 
were eluted with 20 ml acidic glycine buffer. The 9 eluate 
fractions were analyzed by SDS-PAGE and subsequent 
coomassie-blue staining. The two predominant bands 
visible in the coomassie-blue stained gel represent the 
heavy (50 kDa) and light (25 kDa) chain of the purified 
antibodies (arrows). The purified antibody 4-11 contained two unspecific proteins (*) which probably represent 
degradation products. Molecular weights are present on the left. 
 
 
The first four eluate fractions were pooled and the buffer was exchanged to 3.5 ml PBS. 
Afterwards the protein concentration in the samples was determined by UV spectroscopy at 
280 nm and the values were 1 mg/ml for the anti-IL-6R 4-11 antibody and 0.25 mg/ml for the 
anti-IL-6R 14-18 antibody.  
The anti-IL-6R antibody 14-18 was used throughout this study for detection of the human IL-
6R by Western blotting. 
 
4.2 The chemotherapeutic drug doxorubicin induces apoptosis 
in Ba/F3 [gp130/IL-6R] cells. 
 
Pre-B cells stably transfected with the cDNA for the human IL-6R and the human gp130 were 
treated with the chemotherapeutic drug doxorubicin. Doxorubicin causes intrinsic cell death 
by irreversibly inhibition of DNA topoisomerase II, activation of p53 protein and formation of 
reactive oxygen species. Doxorubicin induces apoptosis in Ba/F3 [gp130/IL-6R] cells in a 
dose and time dependent manner (Figure 8). Apoptosis was assessed by annexin V-staining. 
Annexin V is a phospholipid-binding protein with a high specificity and affinity to 
phosphatidylserine (PS) which is exposed to the outer leaflet of the plasma membrane on cells 
undergoing apoptosis. Necrotic cells exhibit membrane permeabilization and will also bind 
annexin V. To distinguish between viable, early apoptotic and necrotic or late apoptotic cells 
propidium iodide was used. Propidium iodide does not penetrate the plasma membrane and 
therefore is excluded from viable and early apoptotic cells. Late apoptotic and necrotic cells 
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were stained with both annexin V and propidium iodide due to the final disintegration of the 
cell.  
Ba/F3 [gp130/IL-6R] cells were exposed to increasing concentrations of doxorubicin and 
analyzed by flow cytometry after 15 hours treatment. The lowest dose of 100 ng/ml 
doxorubicin caused apoptotic cell death in 75 % of the cells. Higher concentrations caused a 
dose-dependent decrease in the number of viable cells (Figure 8A). Similarly, a time-
dependent increase in apoptosis was observed when Ba/F3 [gp130/IL-6R] cells were treated 
with 500 ng/ml doxorubicin for the time periods of 2, 4 and 8 hours (Figure 8B). Except of 
phosphatidylserin exposure doxorubicin-induced apoptosis was accompanied by cleavage of 
the caspase-3 substrate PKCδ. Considerable cleavage of the full length PKCδ to its active 
form could be observed after 6 hours of doxorubicin treatment (Figure 8C). 
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Figure 8: Doxorubicin induced apoptosis of Ba/F3 [gp130/IL-6R] cells in a dose- and time-dependent 
manner. 
A.   Dose-dependent increase of apoptotic cells was observed when Ba/F3 [gp130/IL-6R] cells were treated with 
increasing concentrations of doxorubicin (DOX) (100, 200, 300 and 400 ng/ml) for 15 hours and apoptosis was 
measured using annexin V-FITC/propidium iodide staining and flow cytometry. 
B.  A time-dependent increase in apoptotic and late apoptotic Ba/F3 [gp130/IL-6R] cells was observed when 
cells were treated with doxorubicin (500 ng/ml) for the indicated time periods (2, 4 and 8 hours) before 
measurement of apoptosis. Annexin V-FITC staining is represented on the x-axis and propidium iodide staining 
on the y-axis. The percentage of viable (lower left quadrant), apoptotic (lower right quadrant) and late apoptotic 
(upper right quadrant) cells are indicated.  
C.  When Ba/F3 [gp130/IL-6R] cells were treated with doxorubicin (500 ng/ml), induction of apoptosis was 
accompanied by a time dependent (6 and 8 hours) cleavage of the caspase-3 substrate PKCδ as demonstrated by 
immunoblotting (c-PKCδ: cleaved-PKCδ). 
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4.3 Soluble IL-6R release during doxorubicin-induced 
apoptosis of Ba/F3 [gp130/IL-6R] cells 
 
Ba/F3 [gp130/IL-6R] cells underwent apoptosis after treatment with the chemotherapeutic 
drug doxorubicin. To investigate the fate of the IL-6R during programmed cell death, 
supernatants and lysates of Ba/F3 [gp130/IL-6R] cells were examined by Western blot 
analysis upon induction of apoptosis. Apoptosis was induced for different time points with 
500 ng/ml doxorubicin. In immunoprecipitation experiments with antibodies directed against 
the extracellular domain of the IL-6R, increasing amounts of the 65 kDa IL-6R ectodomain 
were precipitated from cell culture supernatants of apoptotic cells with time after doxorubicin 
treatment. While an increase of the soluble form of the IL-6R (sIL-6R) was detectable after 4 
hours of doxorubicin treatment the amount of cellular IL-6R decreased in the lysates (Figure 
9A, B). As positive control, Ba/F3 [gp130/IL-6R] cells were treated for 2 hours with PMA, a 
well-known inducer of IL-6R shedding (Figure 9B).  
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Figure 9: Time dependent release of the IL-6R from doxorubicin treated Ba/F3 [gp130/IL-6R] cells.  
A. Ba/F3 [gp130/IL-6R] cells were treated for 2, 4 and 8 hours with 500 ng/ml doxorubicin (DOX). Soluble IL-
6R was immunoprecipitated from conditioned media using the polyclonal α-IL-6R serum 6.2 and subsequently 
visualized by Western blot analysis using the α-IL-6R mAB 14-18. Reciprocal Western blot analysis of cell 
lysates was performed using 14-18 mAB and α-β-actin mAB, which was used as a loading control. 
B. Ba/F3 [gp130/IL-6R] cells were treated for 2, 4 and 8 hours with 500 ng/ml doxorubicin (DOX) or 2 hours 
with the phorbol ester PMA (100 nM). Western blot analysis was performed as described in A. 
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Non-apoptotic as well as early and late stage apoptotic Ba/F3 [gp130/IL-6R] cells were 
identified using flow cytometry in combination with annexin V and propidium iodide. To 
monitor IL-6R cell surface expression during apoptosis, doxorubicin treated Ba/F3 [gp130/IL-
6R] cells were stained additionally with the anti-IL-6R antibody M91. After 6 hours of 
doxorubicin treatment three populations were detectable in the annexin V/propidium iodide- 
staining: the annexin V-negative/propidium iodide-negative cell population representing the 
viable cells, the annexin V-positive/propidium iodide-negative cell population representing 
the early apoptotic cells and the annexin V-positive/propidium iodide-positive cell population 
representing the late apoptotic cells (Figure 10, left). The three populations were gated 
separately and IL-6R surface expression was measured for each population (Figure 10, right). 
Examining the IL-6R levels revealed that its surface expression was decreased in annexin V-
positive and annexin V/propidium iodide double-positive cells. Early as well as late apoptotic 
cells showed similar IL-6R cell surface decrease indicating that loss of IL-6R surface 
expression is an early apoptotic event. 
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Figure 10: Loss of cell surface IL-6R during early stages of doxorubicin-induced apoptosis in Ba/F3 
[gp130/IL-6R] cells.   
Ba/F3 [gp130/IL-6R] cells were treated for 6 hours with doxorubicin and multiparameter FACS staining was 
performed with propidium iodide, annexin V-FITC and the α-IL-6R M-91 mAB. Annexin V-FITC staining is 
represented on the x-axis and propidium iodide staining on the y-axis of the dot plot (left). The three cell 
populations (viable, early apoptotic and late apoptotic) are indicated. Each population was gated and IL-6R cell 
surface expression was monitored on the histogram (right). IL-6R cell surface expression is represented on the x-
axis. 
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4.4 Shedding of the IL-6R from the cell surface of apoptotic 
Ba/F3 [gp130/IL-6R] cells. 
 
Doxorubicin treatment of Ba/F3 [gp130/IL-6R] cells led to enhanced sIL-6R release and to 
downregulation of membrane-bound IL-6R on the cell surface. To examine whether this 
events occurred through ectodomain shedding of the membrane-bound IL-6R, Ba/F3 
[gp130/IL-6R] cells were stimulated with doxorubicin in the presence of the hydroxamic acid-
based inhibitor marimastat. Marimastat is a broad-spectrum metalloprotease inhibitor (active 
against both matrix metalloproteases and ADAM proteases), which has been shown to 
abrogate proteolysis of several ADAM10 and ADAM17 substrates (77). Cotreatment of the 
doxorubicin-treated Ba/F3 [gp130/IL-6R] cells with marimastat completely blocked 
generation of the soluble IL-6R indicating that the IL-6R is shed from the cell surface during 
apoptosis by metalloprotease activity (Figure 11). Marimastat did not prevent programmed 
cell death as judged by annexin V-staining (Figure 12). 
 
 
Figure 11: Doxorubicin treatment induced 
metalloproteinase mediated shedding of the 
IL-6R in Ba/F3 [gp130/IL-6R] cells. 
 Exposure of Ba/F3 [gp130/IL-6R] cells to 500 
ng/ml doxorubicin (DOX) for 8 hours resulted in 
metalloproteolytic release of sIL-6R into the 
supernatant as shown by complete inhibition of 
the release by marimastat (10 µM). Marimastat 
was added to the cells 15 minutes prior doxorubicin stimulation. Western blot analysis was used as outlined in 
Figure 9 to monitor levels of sIL-6R and IL-6R. 
 
 
4.5 Shedding of the IL-6R during apoptosis is mediated by the 
metalloprotease TACE (ADAM17) 
 
It was previously described that shedding of the IL-6R after PMA treatment or cholesterol 
depletion was mediated by the metalloprotease ADAM17 and to a lesser extent by ADAM10 
(77). To identify the sheddase which is responsible for apoptosis-induced IL-6R shedding two 
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further hydroxamate-based metalloprotease inhibitors were used. The inhibitor GW280264X 
(GW) has the ability to potently block the activity of ADAM10 and ADAM17, whereas 
GI254023X (GI) inhibits ADAM10 100-fold better then ADAM17 (161) (Table 2).  
 
 
Compound ADAM17 ADAM10 ADAM10 potency/
ADAM17 potency a)
GI254023X
GW280264X
541
8.0
5.3
11.5
102
1.4
IC50 (nM) Selectivity
 
 
Table 2: Potency of the compounds GW280264X and GI254023X for inhibition of recombinant ADAM17 
and ADAM10 ectodomain.  
The inhibitor concentration leading to half maximal inhibition (IC50) of recombinant TACE or ADAM10 (a) 
Potency is defined as 1/IC50). The 2 compounds differ in their capacity to block the activities of the two 
metalloproteinases ADAM17 (TACE) and ADAM10. The compound GW280264X potently blocked both 
recombinant enzymes. The Compound GI254023X, however, possessed comparable inhibitory potency for 
ADAM10 and blocked TACE with more than 100-fold reduced potency. Adopted from (162). 
 
 
The two inhibitors were tested for their ability to block IL-6R shedding during apoptosis. As 
control, Ba/F3 [gp130/IL-6R] cells were treated with PMA, a well known inducer of 
ADAM17-mediated IL-6R shedding. As shown in Figure 12, the ADAM10/ADAM17-
specific inhibitor GW280264X blocked the cleavage in unstimulated, PMA-stimulated as well 
as in doxorubicin-treated cells. The selective ADAM10 inhibitor blocked the constitutive 
cleavage of the IL-6R but hardly affected the cleavage of PMA and doxorubicin-treated cells. 
Thus the inhibitor profile indicated that the constitutive shedding of the IL-6R is mediated by 
ADAM10 whereas the PMA- and doxorubicin-inducible cleavage is mediated by ADAM17 
activity in Ba/F3 [gp130/IL-6R] cells. Both metalloprotease inhibitors did not interfere with 
the progression of apoptosis as judged by annexin V-staining (Figure 12). 
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 Figure 12: The metalloprotease inhibitor 
GW280264X prevented the proteolytic 
cleavage of the IL-6R during doxorubicin 
treatment. 
A. Ba/F3 [gp130/IL-6R] cells were treated for 8 
hours with 500 ng/ml doxorubicin (DOX) in 
presence of 10 µM marimastat, 3 µM 
GW280264X (GW) and 3 µM GI254023X (GI). 
FACS staining was performed with propidium 
iodide and annexin V-FITC to monitor 
apoptosis. The percentage of viable (lower left 
quadrant), apoptotic (lower right quadrant) and 
late apoptotic (upper right quadrant) cells are 
indicated.  
B.  Ba/F3 [gp130/IL-6R] cells were treated for 8 
hours with 500 ng/ml doxorubicin (DOX) or for 
2 hours with 100 nM PMA in the presence or 
absence of the metalloprotease inhibitors 
GW280264X (GW, 3 µM) and GI254023X (GI, 
3 µM). Inhibitors were added 15 minutes prior to 
stimulation. Western blot analysis was used as 
outlined in Figure 9 to monitor levels of sIL-6R, 
IL-6R and β-actin. 
C. Flow cytometric analysis of the IL-6R from 
doxorubicin treated Ba/F3 [gp130/IL-6R] cells. 
The cells were treated with the metalloprotease 
inhibitors GI254023X (GI, 3 µM), GW280264X 
(GW, 3 µM) and marimastat (10 µM) in the 
presence or absence of 500 ng/ml doxorubicin. 
The cells were harvested after 8 hours 
incubation, stained with the α-IL-6R antibody 
M91 (1 µg/ml) and subsequent analyzed by flow 
cytometry. The analysis showed that apoptotic 
cells lost cell surface expression of the IL-6R. 
The level of IL-6R surface expression was 
similar in doxorubicin-treated cells and in viable cells when metalloprotease activity was blocked with the broad-
spectrum metalloprotease and the combined ADAM17/ADAM10 inhibitors but not with the specific ADAM10 
inhibitor. 
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4.6 Ba/F3 [gp130/IL-6R] cells undergo apoptosis after cytokine 
deprivation 
 
Ba/F3 cells are dependent on IL-3 for their survival and proliferation. Ba/F3 cells stably 
transfected with the cDNA coding for human gp130 and IL-6R respond additionally to the 
cytokine IL-6. Both cytokines, IL-3 and IL-6, induce the expression of genes for promotion of 
cell growth and prevention of apoptosis. Thus, Ba/F3 cells are dependent on their respective 
cytokines for growth and undergo apoptosis upon cytokine deprivation. Cytokine withdrawal 
was used as a physiological stimulus to trigger intrinsic programmed cell death which is 
associated with loss of mitochondrial membrane potential, release of cytochrome c into the 
cytosol as well as activation of caspases. Ba/F3 [gp130/IL-6R] cells were cultured in the 
presence of IL-6 or IL-3. 12 hours after IL-6 or IL-3 withdrawal, Ba/F3 [gp130/IL-6R] cells 
begun to undergo apoptosis as judged by annexin V/propidium iodide-staining or 
nucleosomal DNA fragmentation analysis (Figure 13). 24 hours cultivation in absence of IL-3, 
led to complete degradation of the nuclear DNA in nucleosomal fragments (Figure 13, 
SubG1-peak) and 24 hours of IL-6 deprivation led to approximately 40% annexin V-positive 
Ba/F3 [gp130/IL-6R] cells. 
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Figure 13: Cytokine deprivation of Ba/F3 [gp130/IL-6R] cells induced apoptosis. 
A. Ba/F3 [gp130/IL-6R] cell were cultured for 3 weeks in IL-3 containing cultivation medium. The cells were 
washed 3 times with PBS and cytokine deprived for the indicated time periods. Afterwards the cells were 
permeabilized with 70 % methanol and stained with propidium iodide prior analysis by flow cytometry.  Viable 
cells showed no detectable DNA laddering. After 12 and 24 hours of IL-3 deprivation, apoptotic cells were 
detected in the ‘sub-G1 peak’. 
B.  Ba/F3 [gp130/IL-6R] cell were cultured for 3 weeks in IL-6 supplemented cultivation medium. The cells 
were washed 3 times with PBS and cytokine deprived for the indicated time periods. Annexin V-
FITC/propidium iodide-staining was performed as described in Figure 8. 
 
 
4.7 Shedding of the IL-6R after cytokine deprivation of Ba/F3 
[gp130/IL-6R] cells 
 
Apoptosis induced by doxorubicin treatment led to enhanced IL-6R shedding. To investigate 
whether a different apoptotic stimulus has the same impact on the proteolytic cleavage of the 
IL-6R, Ba/F3 [gp130/IL-6R] cells were cytokine deprived for different time periods. 
Generation of the soluble IL-6R as well as the membrane-bound form was monitored by 
A. 
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Western blot and flow cytometry analysis. As depicted in Figure 14, intrinsic apoptosis 
following cytokine withdrawal induced shedding of the IL-6R. In line with data from 
doxorubicin-treated Ba/F3 [gp130/IL-6R] cells, ectodomain shedding after cytokine 
deprivation was completely inhibited by marimastat (pan-metalloprotease inhibitor) and 
almost completely by the ADAM10/ADAM17-specific inhibitor GW280264X but not by the 
ADAM10-specific inhibitor GI254023X. 
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Figure 14: Cytokine withdrawal-induced apoptosis led to ectodomain shedding of the IL-6R. 
A. IL-3 dependent Ba/F3 [gp130/IL-6R] cell were washed 3 times and cultured for 12 and 24 hours in cytokine-
free medium to induce apoptosis. Control cells were maintained over the 24-hour period in the presence of IL-3 
(IL-3-WD, 0h). Marimastat (10 µM) was added as indicated. Lysates and immunoprecipitated supernatants were 
subjected to SDS-PAGE and analyzed by Western blot with the α-IL-6R antibody 14-18. 
B. IL-6 dependent Ba/F3 [gp130/IL-6R] cell were treated and analyzed as described in panel A. The 
metalloprotease inhibitors marimastat (ma, 10 µM), GW280264X (GW, 3µM) and GI254023X (GI, 3 µM) were 
added as indicated. 
C. IL-6 dependent Ba/F3 [gp130/IL-6R] cells were treated and analyzed as described in panel A and B. Cells 
were washed and stained with the α-IL-6R antibody M91 and analyzed by flow cytometry. The isotype control 
staining was performed with viable cells incubated with a monoclonal IgG1 antibody. Cell surface expression of 
the IL-6R is depicted in mean fuorescence intensity (MFI) units on the y-axis. 
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4.8 Extrinsic apoptotic pathways induced by Fas stimulation 
led to IL-6R shedding 
 
Doxorubicin stimulation as well as cytokine withdrawal led to induction of the intrinsic 
apoptotic pathway in Ba/F3 [gp130/IL-6R] cells which was accompanied by shedding of the 
IL-6R from the cell surface. To investigate whether shedding of the IL-6R is stimulated 
during extrinsic apoptosis, further studies were performed with the human hepatocellular 
carcinoma cell line HepG2.  
Fas has been shown to trigger apoptosis by binding to its natural ligand (FasL) or to specific 
anti-Fas agonistic antibodies. HepG2 cells were resistant to FasL or anti-Fas treatment, but 
were rendered susceptible in the presence of cycloheximide (CHX) an inhibitor of protein 
translation. The cytotoxicity induced by anti-Fas/CHX was accompanied by cleavage of 
several caspase substrates like PKCδ and PARP, indicating apoptotic death of HepG2 cells 
(Figure 15A). Although HepG2 cells express endogenously the IL-6R, the protein levels were 
not sufficient to perform Western blot analysis. Therefore HepG2 cells were transiently 
transfected with an expression plasmid coding for the human IL-6R throughout this study. 
Western blot analysis of apoptotic HepG2 cells revealed that the levels of cellular IL-6R were 
reduced after anti-Fas/CHX treatment but not after CHX or anti-Fas treatment alone. The 
cleavage product of PKCδ (cleaved PKCδ) was also only detectable during the combined 
anti-Fas/CHX treatment, indicating that neither CHX nor anti-Fas had the ability to induce 
apoptosis when incubated separately (Figure 15A). Western blot analysis of cell culture 
supernatants revealed that anti-Fas/CHX treatment led to increased sIL-6R release compared 
to control cells (Figure 15B, lane1 and 2). Release of the sIL-6R after anti-Fas/CHX treatment 
was comparable with PMA-induced sIL-6R release. Cellular IL-6R levels decreased after 
PMA/CHX or anti-Fas/CHX treatment, indicating that IL-6R was shed from the cell surface.  
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 Figure 15: Soluble IL-6R release after induction of extrinsic apoptosis by agonistic Fas antibodies. 
A. HepG2 cells were transiently transfected with expression plasmids encoding the human IL-6R or a control 
marker protein EGFP. Cells were treated with cycloheximide (CHX, 100 µM), agonistic α-Fas antibody CH-11 
(α-Fas, 500 ng/ml) or a combination of cycloheximide and agonistic α-Fas antibody CH-11 for 6 hours. Cell 
lysates were prepared and Western blot analysis of IL-6R and the caspase-3 substrate PKCδ was performed (c-
PKCδ: cleaved-PKCδ). Apoptosis visualized by the appearance of c-PKCδ was only detectable in the cells which 
were treated with cycloheximide in combination with α-Fas. 
B. HepG2 cells were transfected with p409-IL-6R expression plasmid and treated with CHX (100 µM, 6 hours), 
CHX (100 µM, 6 hours) + PMA (100 nM added directly to the supernatants after 4 hours cycloheximide 
treatment) or CHX (100 µM, 6 hours) + α-Fas antibody CH-11 (500 ng/ml, 6 hours). After stimulation the 
soluble IL-6R was precipitated from the supernatant and lysates were prepared from the cell pellets. IL-6R and 
sIL-6R were subsequently visualized by Western blot analysis. 
 
 
Inhibitor studies were performed to test whether the formation of sIL-6R during Fas-induced 
apoptosis was mediated by metalloprotease activity. The presence of the broad-spectrum 
metalloprotease inhibitor TAPI-2 markedly blocked formation of sIL-6R. Fas-induced IL-6R 
shedding was also blocked in the presence of the combined ADAM10/ADAM17 
(GW280264X) inhibitor but not in the presence of the selective ADAM10 (GI254023X) 
inhibitor. In line with the data of apoptotic Ba/F3 [gp130/IL-6R] cells, Fas-induced IL-6R 
shedding was mediated by the metalloprotease ADAM17. Since PARP cleavage was not 
inhibited, blockade of the sheddases did not interfere with the progression of apoptosis 
(Figure 16). 
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Figure 16: TAPI and GW280264X 
inhibited shedding of the IL-6R 
extracellular domain during Fas-induced 
apoptosis.   
TAPI-2 (100 µM), GW280264X (GW, 3 
µM) and GI254023X (GI, 3 µM) were added 
to HepG2 cells (transfected with the p409-
IL-6R plasmid) 15 minutes prior induction of 
apoptosis by Fas stimulation. Apoptosis was 
induced as described in Figure 15. After 6 
hours of agonistic α-Fas/CHX treatment the 
sIL-6R was immunoprecipitated from the cell 
culture supernatants and analyzed by Western blotting with α-IL-6R 14-18 antibody. Lysates of treated cells 
were also analyzed by Western blotting with α-PARP antibody (c-PARP: cleaved PARP). Shedding of the IL-6R 
was inhibited in presence of TAPI-2 and GW280264X. The metalloprotease inhibitors did not interfere with the 
apoptotic program since the caspase substrate PARP, which is cleaved only during programmed cell death, was 
present in the cleaved form in presence as well as in absence of the metalloprotease inhibitors (lane 2-5). 
 
 
4.9 Overexpression of dominant-negative ADAM17 suppresses 
IL-6R shedding during PMA stimulation and apoptosis 
 
It has been shown that transfection of a deletion mutant of human ADAM17 lacking the 
prodomain and catalytic domain results in inhibition of the proteolytic release of TNF-α and 
TNF receptor II. This deletion mutant has been postulated to act as a dominant-negative 
inhibitor for endogenous TACE activity (163). The cDNA encoding for the dominant-
negative ADAM17 was amplified from reverse transcribed HepG2 RNA. The amplified 
cDNA encoded the disintegrin, transmembrane and cytoplasmic tail regions of ADAM17. 
The ADAM17 PCR-Product (encoding for amino acids S 474 to C 824) was cloned into the 
spIL-6/pESL vector (Rabe B., Department of Biochemistry, University Kiel, unpublished 
results) and subsequent subcloned into the mammalian expression vector p409b which drives 
the expression of a the dominant-negative TACE N-terminally fused to the signal peptide of 
human IL-6 and C-terminally to the c-myc as well as the his tag. This mutant was referred to 
as DN-ADAM17. 
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Figure 17: Cloning scheme for 
the vectors pESL-DN-
ADAM17 and p409b-DN-
ADAM17.  
Total RNA was isolated from 
HepG2 cells and the mRNA 
was subsequently reverse 
transcribed into cDNA using an 
oligo dT-Primer. The transcript 
encoding for the mutant 
ADAM17 (DN-ADAM17) was 
amplified with the primers D-
ADAM17-up and D-ADAM17-
Not-dn (sequences are listed in 
the appendix) and the resulting 
PCR product was cloned in the 
entry vector pESL between the 
sequence encoding for the 
signal peptide of IL-6 (s.p.) and 
the sequence encoding for a c-
myc and a his tag. To transfer 
the insert into the expression 
vector p409b (destination 
vector) the Gateway® technology (Invitrogen) was used, which is based on the bacteriophage lambda site-
specific recombination system. The recombination occurred between the site-specific attachment (att) sites. The 
attL sites encoded by the pESL vector served as the binding site for the recombination protein mix LR-
ClonaseTM and the recombination occurred between the attL (entry vector) and the attR (destination vector, 
p409b) to give to attB sites. The presence of the ccdB gene allows negative selection of the destination vector 
after recombination (by-product). The CcdB protein interferes with E.coli DNA gyrase, thereby inhibiting 
growth of most E.coli strains. When recombination occurs (between the destination vector and the entry vector) 
the ccbD gene is replaced by the gene of interest. 
 
 
The DN-ADAM17-p409b plasmid was transiently transfected in HepG2 cells and membrane 
localization of DN-ADAM17 was monitored by preparation of membrane fractions. Cell 
surface expression was monitored by surface biotinylation experiments. DN-ADAM17 was 
detected by Western blot analysis in the membrane fraction of transfected HepG2 cells 
whereas endogenous levels of ADAM17 were detectable in the membrane fraction of DN-
ADAM17 overexpressing as well as in control HepG2 cells (Figure 18A). To further analyze 
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the localization of DN-ADAM17 protein, surface biotinylation of transfected HepG2 cells 
was performed. Western blot analysis of streptavidin-precipitated lysates prepared from 
surface-labeled cells revealed that DN-ADAM17 is located on the plasma membrane (Figure 
18B). 
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Figure 18: Membrane localization and surface expression of DN-ADAM17. 
A. Membrane and cytosolic fractions were prepared from mock as well as from DN-ADAM17 expressing 
HepG2 cells. Protein concentrations were determined and 10 µg total protein was loaded on a SDS-gel. 
Subsequent Western blot analysis with α-ADAM17 antibody raised against the C-terminus of human ADAM17 
revealed that both endogenous ADAM17 and DN-ADAM17 were located in the membrane fraction. Several 
bands, probably representing different glycosylation isoforms, were detected in the membrane fraction of DN-
ADAM17 overexpressing HepG2 cells. 
B.  Transiently transfected HepG2 cells with empty vector (mock, p409b) or with p409b/DN-ADAM17 were 
surface-biotinylated with Sulfo-NHS-Biotin. Surface-labeled cells were lysed, and the lysates were precipitated 
with streptavidin-coated agarose beads. The precipitated surface proteins were subjected to SDS-PAGE and 
transferred onto a PVDF membrane for Western blotting. With antibodies against the c-myc tag DN-ADAM17 
was visualized (* unspecific band). 
 
 
Given the information that DN-ADAM17 is expressed and probably transferred to the cell 
surface double transfected HepG2 cells were used for further studies. HepG2 cells were 
transfected with a plasmid coding for the human IL-6R in presence or absence of DN-
ADAM17. IL-6R secretion into the culture supernatant was quantified by a specific IL-6R 
A. B.
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“sandwich”-ELISA. HepG2 cells which expressed only the IL-6R produced on average 4 
ng/ml sIL-6R. PMA as well as doxorubicin treatment led to 2-3 fold increase of secreted IL-
6R. Cotransfection of the DN-ADAM17 mutant did not interfere with constitutive sIL-6R 
release (Figure 19A). However the stimulated sIL-6R release after PMA as well as anti-Fas 
treatment was reduced by 31 % and 28 % respectively, supporting the view that ADAM17 is 
responsible for stimulated IL-6R shedding (Figure 19A, B). IL-6R shedding was not reduced 
to background level after cotransfection of DN-ADAM-17. This might be explained by the 
fact that the amount of the mutant ADAM17 did not largely exceed the amount of 
endogenous ADAM17 (Figure 18A). 
 
Figure 19: Effect of DN-ADAM17 on 
IL-6R shedding after PMA as well as α-
Fas treatment. 
A. HepG2 cells were transiently 
transfected with IL-6R cDNA alone (white 
bars, 1µg p409b-IL-6R, 9 µg p409b) or 
with DN-ADAM17 cDNA (black bars, 
1µg p409b-IL-6R, 9µg p409b-DN-
ADAM17).  Afterwards the cells were 
stimulated with CHX (100 µM, 6 hours) 
with CHX (100 µM, 6 hours)+ PMA (100 
nM added directly to the supernatant after 
4 hours CHX treatment) or CHX (100 µM, 
6 hours) + α-Fas antibody CH-11 (500 
ng/ml, 6 hours). After stimulation soluble 
IL-6R-protein amounts were quantified 
using the sIL-6R specific ELISA. 
Cotransfection of DN-ADAM17 did not 
interfere with baseline shedding but 
reduced PMA as well as α-Fas stimulated 
shedding. 
B. HepG2 cells were transiently transfected with IL-6R cDNA alone (white bars, 1 µg p409b-IL-6R, 9 µg 
p409b) or with DN-ADAM17 cDNA (black bars, 1 µg p409b-IL-6R, 9 µg p409b-DN-ADAM17). 48 hours after 
transfection the cells were lysed and Western blot analysis was performed to monitor DN-ADAM17 expression 
with the α-c-myc antibody. The α-IL-6R antibody 14-18 was used to visualize amounts of IL-6R.  
C. HepG2 cells were transiently transfected and stimulated as described in A. The sIL-6R protein in the culture 
media was quantified using the IL-6R ELISA. The fold increase of the sIL-6R is expressed as percentage of 
baseline shedding which was set to 1 (100 %). Values represent the mean ± SD from 3 independent experiments.  
The P values were determined using the Student’s T test. 
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4.10 ADAM17 activation during apoptosis is caspase dependent 
 
Caspases are major intracellular effectors of intrinsic and extrinsic apoptosis. To establish a 
link between caspase activation and IL-6R shedding, zVAD-fmk (pan-caspase inhibitor) was 
applied 30 minutes prior anti-Fas/CHX treatment. HepG2 cells were stimulated to undergo 
apoptosis by Fas ligation in the presence of zVAD-fmk. Inclusion of zVAD-fmk prevented 
apoptosis and inhibited the processing of the caspase substrates PARP and PKCδ (Figure 20). 
At the same time, shedding of the IL-6R was completely abrogated, indicating that caspase 
activation was required for ADAM17 activation.  
 
 
 
Figure 20: The pan-caspase inhibitor zVAD-
fmk decreased α-Fas-induced shedding of the 
IL-6R.  
HepG2 cells were transiently transfected with 
p409b-IL-6R plasmid and stimulated with α-Fas 
(500 ng/ml)/CHX (100 µM) to undergo apoptosis. 
Control cells were treated with CHX (100 µM). 
The pan-caspase inhibitor zVAD-fmk was added 
as indicated at a concentration of 100 µM 30 
minutes before exposure of the cells to α-
Fas/CHX. After 6 hours of incubation the cell 
culture media as well as the cell pellets were 
harvested. The sIL-6R was immunoprecipitated 
from the supernatants as described in Figure 9. The lysates were directly used for analysis of following proteins: 
IL-6R, cleaved PAPP (c-PARP), cleaved PKCδ (c-PKCδ) and β-actin (loading control). 
 
 
To further investigate if a special caspase isoform was involved in regulating IL-6R shedding 
during apoptosis, more specific inhibitors for the initiator caspase-8, caspase-9, and for the 
effector caspase-3 were used. Apoptosis was induced in HepG2 cells by Fas ligation in 
presence of the different inhibitors. None of the isoform-specific caspase-inhibitors tested led 
to appreciable blockade of IL-6R shedding during apoptosis. However, combined inhibition 
of caspase-8 and -9 reduced IL-6R release, and further multiple inhibition of caspase-3, -8 and 
-9 completely abolished apoptosis-induced IL-6R shedding (Figure 21).  
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Figure 21: Combined inhibition of 
caspase-8, -9 and -3 led to reduction of α-
Fas-induced IL-6R shedding. 
A.  HepG2 cells overexpressing the IL-6R 
were stimulated with α-Fas (500 ng/ml)/CHX 
(100 µM) in presence of 100 µM zVAD-fmk 
(pan-caspase inhibitor, lane 3), 100 µM 
zDEDV-fmk (caspase-3 inhibitor, lane 4), 
100 µM zIETD-fmk (caspase-8 inhibitor, 
lane 5), 100 µM zLEHD-fmk (caspase-9 
inhibitor, lane 6), zIETD-fmk + zLEHD-fmk 
(50 µM each, lane 7) or zDEDV-fmk + 
zIETD-fmk + zLEHD-fmk (33 µM each, lane 
8). Control cells were incubated only with 
100 µM CHX (lane 1). The caspase 
inhibitors were added 30 minutes prior α-
Fas/CHX stimulation. After 6 hours 
incubation period the sIL-6R-protein was 
precipitated from the culture supernatant and 
visualized by Western blotting using the α-
IL-6R antibody 14-18. The cells were lysed 
and also subjected to Western blot analysis as 
described in Figure 9. 
B. HepG2 cells were treated as described in 
A. and culture media were analyzed in 
triplicates with the sIL-6R ELISA.  
 
 
4.11 Apoptosis-induced IL-6R shedding is PKC-, MAPK- and 
ROS-independent 
 
Using specific metalloprotease inhibitors as well as a dominant-negative ADAM17 variant, 
the metalloprotease ADAM17 was identified as sheddase which mediated IL-6R shedding 
during apoptosis. From the fact that treatment of HepG2 cells with the protein biosynthesis 
inhibitor cycloheximide did not affect IL-6R shedding, enhanced ADAM17 protein synthesis 
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during apoptosis was excluded. To analyze if pre-existing ADAM17 molecules were activated 
during apoptosis HepG2 cells were incubated with anti-Fas antibody for 2, 4 and 6 hours. 
Afterwards the cells were lysed and ADAM17 was immunoprecipitated from the cell lysate 
by using an ADAM17 specific antibody directed against the C-terminus of the protein. 
Western blot analysis of the precipitated lysates revealed that in control cells ADAM17 was 
mainly present in the proform. After induction of apoptosis there was a time dependent 
decrease of the ADAM17 unprocessed proform and at the same time an increase in the active 
mature form detectable (Figure 22).  
 
 
Figure 22: Activation of pre-existing 
ADAM17 molecules during Fas-induced 
apoptosis.  
HepG2 cells were stimulated with 500 
ng/ml α-Fas antibody (CH-11) and CHX 
(100 µM) for the indicated time periods. 
The control cells (0 hours, α-Fas) were 
treated only with cycloheximide for 6 
hours. The cell culture supernatants were 
collected and sIL-6R was precipitated as 
described above. The cell pellets were lysed in 100 µl lysis buffer containing 2 % detergent. Afterwards the 
lysate was diluted 1:10 with PBS (containing protease inhibitors) and supplemented with 3µg α-ADAM17 
antibody (Chemicon) and 50 µl Protein A-Sepharose. After an incubation period of 16 hours, the Protein A- 
Sepharose beads were washed and protein complexes were suspended in 60 µl Lämmli-buffer. 20 µl were loaded 
onto a SDS-Gel. The subsequent Western blot analysis was performed with the α-ADAM17 antibody 
(Chemicon).  
 
 
To investigate the molecular mechanism which led to apoptosis-induced ADAM17 activation 
and subsequent IL-6R shedding, already described activators of metalloproteases were 
analyzed. The phorbol ester PMA, a well-known activator of PKC, has been shown to 
facilitate the shedding of several cell-surface receptors among them also the IL-6R (Figure 9, 
15, 20). The PKC family consists of 11 isoenzymes, which can be subdivided into three 
groups. The convential PKCs (α, βI, βII, γ) depend on Ca2+ and are activated by diacylglycerol 
or the analogon PMA. The novel PKCs (δ, ε, η, θ) are also activated by diacylglycerol but are 
Ca2+- independent. Finally, the atypical PKCs (ζ and λ) are Ca2+- independent and do not 
respond to diacylglycerol (164-166). During apoptosis PKCδ is activated by caspase-3 
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cleavage (Figure 8, 15, 20). It has been reported that proteolytic activation of PKCδ 
contributes to certain features of the apoptotic phenotype, like nuclear fragmentation (127) 
(167) To investigate if a member of the PKC family was involved in ADAM17 activation 
during apoptosis, HepG2 cells were stimulated to undergo apoptosis by anti-Fas treatment in 
the presence of the PKC inhibitors GF109203X (pan-PKC inhibitor) and Gö6976 (convential 
PKC inhibitor). As control, HepG2 cells were stimulated with PMA, a well known activator 
of PKCs. Both inhibitors effectively blocked PMA-induced IL-6R shedding indicating that 
PMA led to activation of a convential PKC family member, which subsequent mediate the 
activation of ADAM17. Contrary to PMA-induced shedding, Fas-induced shedding could not 
be blocked by any of the PKC inhibitors, suggesting that upon apoptosis induction, ADAM17 
was activated in a PKC-independent manner. Inhibition of PKCs did not inhibit caspase-3 
cleavage and activation, since PKCs are believed to act downstream of caspase-3. 
 
 
 
 
Figure 23: Apoptosis-induced shedding of 
the IL-6R was PKC independent. 
A. HepG2 cells overexpressing the IL-6R 
were incubated with PMA (100 nM) for 2 
hours. The pan-PKC inhibitor GF109203X 
(5 µM) as well as the conventional PKC 
inhibitor Gö6976 (1 µM) were added 15 
minutes prior PMA stimulation as indicated. 
The sIL-6R was immunoprecipitated from 
the cell culture supernatants as described in 
Figure 9. The cells were lysed and the lysate 
was subjected to SDS-PAGE. Western blot 
analysis was performed with the α-IL-6R 
antibody 14-18. 
B. HepG2 cells overexpressing the IL-6R 
were incubated with α-Fas (500 ng/ml)/CHX 
(100 µM) for 6 hours. Control cells (lane 1) 
were incubated with CHX (100 µM) alone. 
Inhibitors were added as described in A. 
Western blot analysis was also performed as 
described in A (c-caspase-3, cleaved caspase-
3).   
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Besides of PKCs it has been postulated that PMA-induced ADAM17 activation is mediated 
by serine/threonine kinases belonging to the mitogen-activated protein kinase (MAPK)-
family. During the last years accumulating studies have informed the view that the MAPKs 
Erk and p38 mediate most of the shedding-activation signals triggered by growth factors, 
stress and commonly used non-physiological drugs (168, 169). Phosphorylation of the 
cytoplasmic tail of ADAM17 (threonine735) by the MAP kinase Erk was associated with 
subsequent ADAM17 activation (89). Osmotic stress-induced ADAM17 activation (e.g. 
sorbitol) can be mediated via the MEK/Erk pathway or the p38-MAPK pathway. It has been 
shown that osmotic stress-mediated HB-EGF shedding is controlled by p38 activity 
implicating that p38-MAPK is an upstream activator of ADAM metalloproteases (170). Thus 
MAPK pathways participate in regulating ADAM-mediated ectodomain shedding of various 
substrates.  
To test whether p38- or Erk-MAPKs were upstream regulators of apoptosis-induced IL-6R 
shedding, transiently transfected HepG2 cells were stimulated to undergo apoptosis by Fas 
ligation in presence of the p38 inhibitor SB202190 or the Erk inhibitor U0126. Apoptosis-
induced IL-6R shedding was unaffected in the presence of both inhibitors suggesting that 
MAPK pathways were not involved in ADAM17 activation during programmed cell death. 
 
 
 
 Figure 24: Apoptosis-induced shedding was p38- and Erk-
MAPK independent.  
Transiently transfected HepG2 cells with the expression plasmid 
p409b-IL-6R were incubated with CHX (100 µM, 6 hours, bar 1) 
or with CHX (100 µM)/α-Fas (500 ng/ml, 6 hours, bar 2) to 
undergo apoptosis. The p38-MAPK inhibitor SB202190 (10 µM) 
as well as the Erk-MAPK inhibitor U0126 (5 µM) were added as 
indicated 15 minutes prior α-Fas treatment.  The cell culture 
supernatants were collected and analyzed with the specific sIL-6R ELISA. The standard deviation was 
determined from triplicate values. 
 
 
Reactive oxygen species (ROS, e.g. H2O2) have been shown to activate ADAM17. The 
proposed mechanism was that ROS mediate the release of the inhibitory N-terminal 
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sulfhydryl moiety of the ADAM17 prodomain and release it from coordination with the 
catalytic zinc of the metalloprotease domain, thus activating TACE.  
Activation of the Fas receptor results in signal transduction pathways which lead to 
cytochrome c release and ROS formation. Although the major biological process leading to 
oxygen-derived generation of ROS is electron transport associated with mitochondrial 
membranes, the membrane-bound NADPH oxidase appeared to play a role in production of 
ROS in conjunction with apoptosis. The NADPH oxidase consists of several components and 
all of them have been detected in HepG2 cells (171, 172). To test whether the production of 
ROS is involved in ADAM17 activation and subsequent shedding of the IL-6R during 
apoptosis, the flavine oxidase inhibitor DPI and the ROS-scavengers 1,3-dimethyl-2-thiourea 
(DMTU) and n-propyl-gallete (nPG) were used. HepG2 cells were stimulated to undergo 
apoptosis by Fas treatment in presence of the NADPH oxidase inhibitor or the ROS-
scavengers. Anti-Fas treatment led to a three fold increase of sIL-6R in the cell culture 
supernatants. This effect could not be blocked by DPI or the combined treatment of DMTU/n-
PG suggesting that reactive oxygen species were not involved in the signal transduction 
leading to ADAM17 activation after induction of apoptosis. 
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Figure 25: The NADPH oxidase inhibitor DPI as well as the ROS-scavengers DMTU and nPG did not   
inhibit sIL-6R release from α-Fas treated cells.  
A. HepG2 cells were treated with α-Fas (500 ng/ml)/CHX (100 µM) for 6 hours in the presence or absence of the 
ROS-scavengers DMTU (20 mM) and nPG (100 µM). ROS-scavengers were added 30 minutes prior α-Fas 
stimulation. The cell culture supernatants were collected and analyzed with the specific sIL-6R ELISA. The 
standard deviation was determined from triplicate values. 
B. HepG2 cells were treated with α-Fas (500 ng/ml)/CHX (100 µM) for 6 hours in the presence or absence of the 
NADPH inhibitor DPI (10 µM). DPI was added 30 minutes prior α-Fas stimulation. The cell culture supernatants 
were collected and analyzed as described in A. 
A. B. 
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4.12 IL-6R shedding is not required to terminate IL-6-induced 
STAT3 phosphorylation during apoptosis 
 
IL-6 mediated signal transduction involves first binding of the α-chain IL-6R and subsequent 
recruitment of two gp130 subunits. The signals which are transmitted into the cells by gp130 
lead to induction of pro-survival pathways. It is known for example that Bcl-XL and Bcl-2, 
which represent anti-apoptotic members of the Bcl-family, are target genes for the activated 
transcription factor STAT3. Shedding of the IL-6R during apoptosis resulted in diminished 
cell surface expression of the receptor. Without the α-chain, cells become unresponsive to IL-
6. To investigate if apoptosis-induced shedding of the IL-6R is required to terminate IL-6-
induced signal transduction, Ba/F3 [gp130/IL-6R] cells were used. The cells were treated with 
doxorubicin for 2 hours, 4 hours and 6 hours and subsequently stimulated for 10 minutes with 
IL-6 to induce STAT3 phosphorylation. Upon induction of apoptosis, the cells become less 
susceptible to IL-6 stimulation as indicated by decreasing STAT3 phosphorylation after 4 and 
6 hours. Surprisingly, blocking IL-6R shedding during apoptosis by the broad-spectrum 
metalloprotease inhibitor marimastat, did not increase the amount of phosphorylated STAT3, 
indicating that the role of IL-6R shedding is not termination of STAT3 activation. 
Results 
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Figure 26: STAT3 phospho-
rylation was abrogated during 
apoptosis. 
A. Schematic representation of 
the experiment described in B. 
Ba/F3 [gp130/IL-6R] cells were 
stimulated to undergo apoptosis 
by doxorubicin treatment. During 
apoptosis the IL-6R is shed from 
the cell surface and the cells 
become unresponsive to IL-6. 
Induction of apoptosis in 
presence of the metalloprotease 
inhibitor marimastat, abrogated 
shedding and rescued IL-6R cell 
surface expression.  
B. Ba/F3 [gp130/IL-6R] cells 
were washed 3 times and 
incubated for 0, 2, 4 and 6 hours 
with 500 ng/ml doxorubicin, in 
serum-free medium and in the 
absence of IL-6. The 
metalloprotease inhibitor 
marimastat was added as indicated to prevent IL-6R shedding at a concentration of 10 µM. After the induction 
period, the cells were centrifuged and resuspendet in medium containing IL-6 (200 ng/ml) or without IL-6 as 
control for 10 min. The cells were immediately lysed and the proteins were immunoblotted with α-p-STAT3 
antibody. Reprobing with an α-STAT3 specific antibody ensured comparable protein loading. 
 
 
Apoptotic cells did not respond to IL-6 stimulation even when IL-6R shedding was prevented 
by metalloprotease inhibition. Upon induction of apoptosis gp130 mediated STAT3 activation 
was abrogated by different molecular mechanism then IL-6R shedding. Furthermore it was 
analyzed if the sIL-6R generated during apoptosis can bind IL-6 and activate surrounding 
cells via trans-signalling. HepG2 cells overexpressing the IL-6R were stimulated to undergo 
apoptosis by anti-Fas treatment in presence or absence of the pan-caspase inhibitor zVAD-
fmk. The conditioned supernatants were harvested and supplemented with recombinant IL-6, 
to allow formation of [sIL-6R/IL-6] complexes. Afterwards Ba/F3 cells overexpressing the 
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human gp130 were stimulated with the conditioned supernatants. Ba/F3 [gp130] cells can 
induce STAT3 phosphorylation only following stimulation with IL-6 in the presence of the 
sIL-6R. As shown in Figure 27, only conditioned supernatants from apoptotic HepG2 cells 
induced STAT3 phosphorylation in Ba/F3 [gp130] cells, indicating that the sIL-6R generated 
during apoptosis is biologically active and can promote IL-6 trans-signalling. 
 
 
Figure 27: The sIL-6R generated 
during apoptosis was biological 
active. HepG2 cells were transfected 
with p409b-IL-6R and subsequent 
treated with CHX (100 µM, control), 
α-Fas (500 ng/ml)/CHX (100 µM) or 
α-Fas/CHX + zVAD-fmk (100 µM). 
The supernatants were harvested and 
supplemented with 200 ng/ml 
recombinant human IL-6. After an 
incubation period of 30 min, the 
supernatants were used to stimulate Ba/F3 [gp130] cells for 10 min. Afterwards the Ba/F3 [gp130] cells were 
spun down (13,000 rpm, 30sec, 4°C), the supernatant was discarded and the cell pellet was frozen in liquid 
nitrogen. Then the cell pellet was resuspendet in 100 µl 2x Lämmli buffer and 20 µl were loaded on a SDS-gel. 
Western blot analysis was performed as described in Figure 26B. 
 
 
4.13 Soluble IL-6R was released from apoptotic primary human 
neutrophils 
 
To place these studies in a more physiological context apoptosis was induced in primary 
human neutrophils. In previous studies it was shown that human neutrophils express 
constitutively both, IL-6R mRNA and the mature protein (173, 174). Additionally it was 
shown that expression of the IL-6R on the cell surface of neutrophils was reduced after fMLP 
or PMA treatment. This loss correlated with a decrease in surface L-selectin expression, 
suggesting that the IL-6R was shed from neutrophils upon stimulation (174). 
Human neutrophils were isolated from blood of healthy donors and apoptosis was 
subsequently induced by Fas stimulation, UV irradiation or doxorubicin treatment. Fas 
stimulation and UV treatment induced apoptosis of neutrophils with 45 % and 90 % of the 
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cells being annexin V-positive after 6 hours. Doxorubicin did not induce apoptosis in primary 
human neutrophils since there were no annexin V-positive cells detectable after treatment 
(Figure 28A). Western blot analysis of the cell culture media from apoptotic cells revealed 
increasing amounts of the IL-6R ectodomain compared to the control cells. 
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Figure 28: Induction of 
apoptosis in primary 
human neutrophils.  
A. Primary human 
neutrophils were isolated as 
described in Material and 
Methods. The cells were 
seeded at a density of 5 x 
106 cells/ml RPMI 
cultivation medium and 
apoptosis was induced as 
indicated. For UV 
treatment the cells were exposed to 200,000 µJ/cm2 UV and subsequent incubated at 37°C for 6 hours. The 
agonistic α-Fas antibody CH-11 (500 ng/ml) as well as doxorubicin (DOX) were added directly to the cultivation 
medium. Apoptosis was measured using annexin V-FITC/propidium iodide staining and flow cytometry. 
Annexin V-FITC staining is represented on the x-axis and propidium iodide-staining on the y-axis. The 
percentage of viable (lower left quadrant), apoptotic (lower right quadrant) and late apoptotic (upper right 
quadrant) cells are indicated.  
B. Neutrophils were treated as described in panel A and the culture supernatants were immunoprecipitated with 
the polyclonal 6.2 α-IL-6R serum. The precipitated proteins were subjected to SDS-PAGE and Western blot 
analysis was performed with the α-IL-6R 14-18 antibody. Lower panel in B. shows intensities of the bands 
determined by densitometric quantification (Image J, NIH).  
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For further experiments primary human neutrophils were UV irradiated since this method led 
to high amounts of early apoptotic cells. Neutrophils were isolated from three different donors 
and apoptosis was induced in presence of the pan-metalloprotease inhibitor TAPI-2, the 
combined ADAM10/ADAM17 (GW) inhibitor and the selective ADAM10 (GI) inhibitor. 
Cell culture supernatants were prepared 6 hours after UV irradiation, and the levels of sIL-6R 
were assessed by Western blotting. To monitor apoptosis neutrophils were stained 
additionally with annexin V-FITC and propidium iodide and analyzed by flow cytometry 
(Table 3). As indicated in Figure 29, sIL-6R was shed from apoptotic neutrophils after UV 
irradiation to a larger extent than from untreated (viable) cells. The generation of sIL-6R 
during apoptosis was inhibited by TAPI-2 and by GW280264X but not by GI254023X. These 
data indicate that also in primary human neutrophils ADAM17, and not ADAM10, was 
responsible for the shedding of the IL-6R during apoptosis.  
 
 
0.6%94%6%UV irradiation in presence 
of GI254023X (3µM)
0.5%91%8%UV irradiation in presence 
of GW280264X (3µM)
1.4%94%4%UV irradiation in presence 
of TAPI (10 µM)
0.4%93%6%UV irradiation
0.4%7%91%untreated control
late
apoptotic
neutrophils
early
apoptotic
neutrophils
viable
neutrophils
 
 
Table 3: Neutrophil apoptosis was not altered in the presence of different metalloprotease inhibitors. 
Primary human neutrophils were UV irradiated (200,000 µJ/cm2) and afterwards incubated for 6 hours at 37°C. 
The cells were spun down and stained with annexin V-FITC/propidium iodide to monitor apoptosis. Via flow 
cytometry the viable (annexin V-negative/propidium iodide-negative), early apoptotic (annexin V- 
positive/propidium iodide-negative) and late apoptotic (annexin V-positive/propidium iodide-positive) cell 
populations were determined. 
Results 
 
  74 
100
300
500
un
tre
ate
d UV
UV
+T
AP
I
UV
+G
I
UV
+G
W
in
te
ns
ity
donor I donor II
100
300
500
700
un
tea
ted UV
UV
+ T
AP
I
UV
+G
I
UV
+G
W
in
te
ns
ity
UV - + + + +
TAPI GI GW
500
1000
1500
2000
un
tre
ate
d UV
UV
+T
AP
I
UV
+G
I
UV
+G
W
in
te
ns
ity
donor III
100%
summary
0,5
1
1,5
2
2,5
3
un
tre
ate
d
x-
fo
ld
in
cr
ea
se
in
 
sI
L-
6R
 re
le
as
e
UV
UV
+T
AP
I
UV
+G
I
UV
+G
W
p < 0.047
p < 0.022
p < 0.034
UV - + + + +
TAPI GI GW
sIL-6R
UV - + + + +
TAPI GI GW
sIL-6R
sIL-6R
 
 
Figure 29: IL-6R was shed from apoptotic human neutrophils. 
Neutrophils were isolated from three healthy donors and apoptosis was induced by UV irradiation. The 
metalloprotease inhibitors TAPI-2 (10 µM), GW280264X (GW, 3 µM) and GI254023X (GI, 3 µM) were added 
as indicated 15 minutes prior UV irradiation. Soluble IL-6R was immunoprecipitated from the cell culture 
supernatant and subsequently analyzed by Western blotting. The lower panels show intensities of the protein 
bands determined by densitometric quantification. The intensities of the sIL-6R protein band of the three 
experiments were summarized and expressed as a percentage of the control (set to 100 %). The P values were 
determined using the Student’s T test. 
 
 
 
Results 
 
  75 
Apoptosis of Fas stimulated neutrophils could be prevented by the addition of the caspase-3 
inhibitor zDEDV-fmk but not by recombinant IL-6 or the fusion protein HIL-6 (sIL-6/IL-6R, 
(152)), again indicating that the role of IL-6R-shedding is not to render the cells unresponsive 
to IL-6 but to induce IL-6 trans-signalling in neighbouring non-apoptotic cells. 
 
 
Figure 30: Apoptosis of neutrophils was not 
prevented by IL-6 or HIL-6.  
Peripheral blood neutrophils were isolated as described 
in Materials and Methods and were stimulated with 
500 ng/ml agonistic α-Fas antibody CH-11 and 
incubated for 7 hours in RPMI-medium. Recombinant 
human IL-6 (10 ng/ml), recombinant human Hyper-IL-
6 (fusion protein of IL-6/IL-6R, 10 ng/ml) and the 
caspase-3 inhibitor zDEDV-fmk (100 µM) were added 
to the culture medium together with the α-Fas antibody 
as indicated. To monitor apoptosis the cells were 
stained with annexin V-FITC and analyzed by flow 
cytometry. Annexin V-FITC fluorescence intensity is 
represented on the x-axis. 
 
 
 
 
 
 
 
 
4.14 The murine air pouch model of acute inflammation 
 
Induction of apoptosis in human neutrophils led to enhanced shedding of the IL-6R. 
Neutrophils, which release the IL-6R, play a dominant role in host defence. To investigate the 
role of IL-6R shedding in vivo a mouse model of inflammation was used where neutrophils 
infiltrate the inflamed area as first host defence reaction. Because neutrophils represent a 
short-lived cell population, they undergo apoptosis during resolution of inflammation and the 
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host defence is carried over by monocytes, which represent the second cell population 
infiltrating the inflamed area. Thus, resolution of the neutrophil infiltrate is associated with a 
subsequent recruitment of mononuclear cells (175). It has been described previously that 
neutralization of the IL-6R reduced the infiltration of immune cells in the murine carrageenan 
air pouch model of acute inflammation, but it was not demonstrated whether this reduction 
affected neutrophilic or mononuclear phagocytic cells (176). To demonstrate the importance 
of IL-6R signalling during acute inflammation and to discriminate between the neutrophilic 
and mononuclear cell population, the mouse air pouch model of acute inflammation was used. 
The air pouch model of acute inflammation described by Sedgwick et al (157) consists of a 
subcutaneous injection of air on the back of mice. This procedure results in the formation of 
an air pouch with lining cells morphologically and functionally similar to the synovium. The 
non-inflamed cavity is lined by a thin layer of fibroblasts and macrophage-like cells. The 
injection of the irritant carrageenan (a sulphated polysaccharide obtained from the alga 
Chondrus crispus) induces a local inflammatory response and the pouch serves as a reservoir 
of cells and mediators in the fluid that accumulate locally. The kinetic of leukocyte 
recruitment during carrageenan-induced inflammation in the air pouch was analyzed in 
previous studies. 24 hours after carrageenan injection most of the leukocytes which were 
recruited into the air pouch were polymorphonuclear leukocytes (PMN, neutrophils). The cell 
population changed from 48 hours after treatment to a prevalence of mononuclear leukocytes 
(monocytes, macrophages) (177).  
Air pouches were formed on the dorsal skin of 8 to 10-week old male C57Bl/6 wildtype mice 
and 6 hours before carageenan injection neutralizing anti-murine IL-6R antibodies (to inhibit 
classic signalling and trans-signalling) or recombinant soluble sgp130-Fc protein (to inhibit 
only trans-signalling) were administered. The mice were sacrificed 72 hours after induction of 
the acute inflammation and total cell numbers, cell numbers of neutrophils and mononuclear 
phagocytes as well as inflammatory mediators were determined. Figure 31 gives a schematic 
overview of the time schedule used in the air pouch experiments. 
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Figure 31: Time schedule of the air pouch experiments.  
Air pouches were formed on the back of C57Bl/6 wildtype mice by injection of 6 ml sterile air. On day three the 
pouches were reinjected with 4 ml of sterile air. On day six the mice were challenged with neutralizing 
antibodies raised against the murine IL-6R or sgp130-Fc intraperitoneally and after 6 hours 1 ml of 1 % 
carrageenan (dissolved in PBS) was injected into the pouch. 72 hours after carrageenan injection the animals 
were sacrificed and the pouches were washed with 3 ml ice cold PBS to obtain the pouch lavage.  
 
 
4.15 Injection of neutralizing IL-6R antibodies led to impaired 
monocyte infiltration in the inflamed air pouch 
 
Two different neutralizing antibodies raised against the murine IL-6R were administered in 8 
to 10 week old male C57Bl/6 wildtype mice before carrageenan injection. A group of five 
mice was challenged with PBS as control, five mice were challenged with 100 µg anti-mouse 
IL-6R (clone D7715A7, diluted in PBS) and finally five mice were challenged with 100 µg 
anti-mouse IL-6R (clone MR-16-1, diluted in PBS). Both antibodies were used in previous 
studies to block signal transduction mediated by the IL-6R (178-180) and were administered 
by intraperitoneal (i.p.) injection. 6 hours after the i.p. injection the mice were challenged 
with 1 % carrageenan solution to induce an inflammatory response. After 72 hours the mice 
were sacrificed, the pouches were washed with 3 ml PBS and the lavage fluid was analyzed in 
terms of cell numbers and inflammatory mediators. Total cell numbers were recorded and 
additionally cell numbers of neutrophils and monocytes were determined by flow cytometry. 
The numbers of total infiltrating cells in the inflamed air pouch was significantly reduced in 
the anti-IL-6R antibody-treated mice to approximately 10 x 106 cells/air pouch compared to 
the PBS-treated mice (20 x 106 cells/air pouch) indicating that IL-6 mediated signal 
Results 
 
  78 
transduction was important for leukocyte recruitment. Neutrophil infiltration was measured 
by flow cytometry with the use of anti-Ly6G antibody, a marker for neutrophils. Compared to 
PBS injection as a control, anti-IL-6R antibody injection slightly decreased the numbers of 
infiltrating neutrophils into the air pouch but not to significant levels. In terms of infiltrating 
monocytes there were significant differences observed between the PBS control group and the 
anti-IL-6R antibody challenged group. Flow cytomerty analysis using the anti-F4/80 antibody 
revealed that administration of anti-IL-6R antibodies led to inhibition of monocyte infiltration 
into the air pouch. These results indicated that blocking IL-6R signalling suppresses events 
upstream of monocyte infiltration. 
 
 
 
Figure 32: IL-6R signalling was 
important for monocyte infiltration into 
the inflamed air pouch. 
A. Air pouches were formed on the back of 
C57Bl/6 wildtype mice (male, 8-10 weeks 
old) as described in Material and Methods. 
After 6 days the mice were injected i.p. 
with 400 µl PBS, 100 µg α-IL-6R 
D7715A7 or 100 µg α-IL-6R MR-16-1, 6 
hours before administration of 1 ml 
carrageenan solution (1 %). Each group 
contained 5 mice. 72 hours later the mice 
were sacrificed, the pouches were washed 
with 3 ml PBS and the total cell numbers 
were determined (neubauer cell chamber). 
Data are represented as mean values ± SD. 
B. 200,000 cells (pouch lavage) were 
stained with α-Ly6G (neutrophilic marker) 
and α-F4/80 (monocytic marker) and 
analyzed by flow cytometry. To obtain 
total numbers of infiltrated neutrophils and 
monocytes the percentages of each cell 
population which were determined by 
FACS analysis were multiplied with the 
total cell numbers. Data are represented as 
mean values ± SD.  
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4.16 “Trans-signalling” rather then “classic signalling” is 
important for monocytic infiltration into the inflamed air 
pouch 
 
Blocking IL-6-mediated signal transduction during acute inflammation by anti-murine IL-6R 
antibodies led to impaired monocytic infiltration into the inflamed area. The use of 
neutralizing antibodies against the IL-6R however blocked both, the classic signalling 
mediated by the membrane-bound IL-6R and the trans-signalling mediated by the soluble 
form of the IL-6R. To distinguish which pathway was important for leukocyte infiltration 
during acute inflammation, mice were challenged with recombinant-soluble gp130 protein 
fused to the Fc region of human IgG1 intraperinoneally before injection of the irritant 
carrageenan into the air pouch. It was showed in previous studies that sgp130 exclusively 
inhibited IL-6 responses mediated by the sIL-6R without interfering with responses mediated 
via the membrane-bound IL-6R or other cytokines of the IL-6 type family (73, 181).  
8-10 weeks old male C57Bl/6 wildtype mice were challenged i.p. with 100 µg of sgp130-Fc 
protein 6 hours before injection of 1 % carrageenan solution into the air pouch. Cell numbers 
of neutrophils and monocytes were determined by flow cytometry, while levels of sgp130 
were assessed by ELISA in the inflamed air pouches and in the serum 72 hours after induction 
of inflammation. High concentrations of circulating sgp130-Fc protein were detected in the 
serum of challenged mice indicating that the protein remained in a stable conformation during 
the entire experimental procedure. The serum concentration 72 hours after injection of 
sgp130-Fc was 17.4 µg/ml whereas approximately tenth part of the sgp130-Fc protein 
circulating in the bloodstream was transmitted to the air pouch cavity (3.5 µg/ml). 
The number of total infiltrating cells was significantly reduced in sgp130-Fc challenged mice 
as compared to PBS control mice. Whereas the cell number in PBS control animals increased 
to 21 x 106/pouch, the inflammatory reaction in the sgp130-Fc challenged mice was markedly 
suppressed to 8.7 x 106 cells/pouch. Additionally in the sgp130-Fc challenged mice the 
proportion of neutrophils and monocytes in the air pouch was strongly reduced. These results 
indicate that impaired leukocyte accumulation during acute inflammation was likely due to 
IL-6 trans-signalling, and not classical IL-6-signalling. 
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Figure 33: IL-6 trans-signalling was 
important for leukocyte recruitment to 
the site of inflammation.  
A. Air pouches were formed on the back of 
C57Bl/6 wildtype mice (male, 8-10 weeks 
old) as described in Material and Methods. 
After 6 days the mice were injected i.p. 
with 400 µl PBS or 100 µg recombinant 
sgp130-Fc protein before administration of 
1 ml carrageenan solution (1 %). Each 
group contained 5 mice. 72 hours later the 
mice were sacrificed, the pouches were 
washed with 3 ml PBS and the serum was 
collected by heart puncture. Soluble gp130-Fc concentrations in the serum as well as in the pouch lavage 
samples were determined by a specific “sandwich”-ELISA for human gp130 (triplicates). Data are represented as 
mean values ± SD. 
B. Total cell numbers were determined in the pouch lavage (neubauer cell chamber). Data are represented as 
mean values ± SD. 
C. 200,000 cells (pouch lavage) were stained with α-Ly6G (neutrophilic marker) and α-F4/80 (monocytic 
marker) and analyzed by flow cytometry. To obtain total numbers of infiltrated neutrophils and monocytes the 
percentages of each cell population which were determined by FACS analysis were multiplied with the total cell 
numbers. Data are represented as mean values ± SD.  
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4.17 Leukocyte recruitment during acute inflammation in IL-6-
deficient mice 
 
The air pouch model of acute inflammation was performed with IL-6-deficient (IL-6-/-) mice. 
It was described before by Romano et al. that IL-6-/- mice showed impaired leukocyte 
recruitment to the site of inflammation (176). However the experiments performed so far 
focus upon early time points of leukocyte recruitment during acute inflammation. Romano et 
al. used the air pouch model and demonstrated that 24 hours after carrageenan injection, IL-6-
/- mice recruit only half of the leukocytes compared to wild type control mice. At this time 
point it is very likely that the main cell population in the pouch cavity consist of infiltrated 
neutrophils. To investigate, if monocyte infiltration was impaired in IL-6-/- mice, consistent 
with the date observed with sgp130-Fc protein and anti-IL-6R challenged mice, the air pouch 
model was performed and two different time points were analyzed: the 12 hours time point 
represented the early stage of inflammation and the 72 hours time point represented the late 
stage of inflammation. In line with already published data, the number of total infiltrating 
cells was significantly reduced in IL-6 -/- mice compared to the wildtype C57Bl/6 animals 12 
hours after carrageenan injection. Further analysis of the infiltrating leukocytes revealed that 
IL-6 -/- mice harboured significantly less neutrophils in the air pouch cavity then the wildtype 
control animals (Figure 34). 
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Figure 34: IL-6-/- mice showed impaired leukocyte recruitment 12 hours after carrageenan injection. 
A. Air pouches were formed on the back of C57Bl/6 wildtype mice (male, 8-10 weeks old, n=5) and 
C57Bl/6/IL-6 -/- mice (male, 8-10 weeks old, n=3) as described in Material and Methods. After 6 days the mice 
were challenged with 1 ml carrageenan solution (1 %). 12 hours later the mice were sacrificed, the pouches were 
washed with 3 ml PBS to obtain the pouch lavage. Total cell numbers were determined in the pouch lavage 
(neubauer cell chamber). Data are represented as mean values ± SD (* p=0.04). 
B. 200,000 cells (pouch lavage) were stained with α-Ly6G (neutrophilic marker) and α-F4/80 (monocytic 
marker) and analyzed by flow cytometry. To obtain total numbers of infiltrated neutrophils and monocytes the 
percentages of each cell population which were determined by FACS analysis were multiplied with the total cell 
numbers. Data are represented as mean values ± SD.  
 
 
Surprisingly, analysis of the infiltrating leukocytes 72 hours after induction of inflammation, 
revealed no significant differences between the IL-6-/- mice and the wildtype control mice in 
terms of infiltrating neutrophils and monocytes. This outcome was not expected since the IL-
6-/- mice showed significantly impaired leukocyte recruitment during the onset of 
inflammation. These results indicate that IL-6 signalling is involved in leukocyte recruitment 
during onset of inflammation but can be compensate by other signal transduction pathways 
onward the inflammatory response. 
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Figure 35: IL-6-/- mice showed normal leukocyte recruitment 72 hours after carrageenan injection. 
A. Air pouches were formed on the back of C57Bl/6 wildtype mice (male, 8-10 weeks old, n=7) and 
C57Bl/6/IL-6 -/- mice (male, 8-10 weeks old, n=7) as described in Material and Methods. After 6 days the mice 
were challenged with 1 ml carrageenan-solution (1 %). 72 hours later the mice were sacrificed, the pouches were 
washed with 3 ml PBS to obtain the pouch lavage. The murine IL-6 specific “sandwich”-ELISA was performed 
with the pouch lavages and data are represented as mean values ± SD (ND: not detectable).  
B+C. Total cell numbers as well as numbers of neutrophils and monocytes were determined as described in 
Figure 34. 
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5 Discussion 
 
5.1 Molecular basis of ADAM 17 activation during apoptosis 
 
Proteolytic processing is of prime importance for regulating the functional properties of cell 
surface proteins. Two large families of zinc-dependent metalloproteases have been described: 
the matrix metalloproteases and the ADAM proteases. ADAM17 (also referred to as TNF-α 
converting enzyme, TACE) cleaves a number of different cell surface proteins or receptors 
involved in a variety of biological processes. Among the numerous substrates of ADAM17 
are several proteins which serve as inflammatory modulators like TNF-α, TNF receptors, L-
selectin, fractalkine and the IL-6R. Proteolytic cleavage of the IL-6R occurs in a constitutive 
fashion and can be additionally stimulated by PMA-mediated PKC activation, treatment of 
cells with bacterial toxins, cholesterol depletion of cellular membranes and treatment of cells 
with C-reactive protein (CRP). Interestingly, all stimuli described so far trigger membrane 
alterations or perturbation (Figure 36). The phorbol ester PMA intercalates into the plasma 
membrane and potently activates PKC family members by recruiting them to the membrane, 
thus mimicking the mechanism of the natural activator, diacylglycerol. Thus, PKC activation 
is mediated by high-affinity binding to the membrane components diacylglycerol and 
phosphatidylserine (182). The acute phase protein CRP has a Ca2+-dependent binding 
specificity for phosphorylcholine, the polar head group of two widely distributed lipids, 
lecithin (phosphatidylcholine, PC) and sphingomyelin (SM) (183, 184). A number of 
observations suggest that at least some of the biological activities of CRP depend on its 
interaction with phospholipids of cell membranes. Besides phospholipids CRP interacts also 
with the complement factor C1q and the immunoglobulin receptors (FcγR) (185). The 
bacterial toxins Streptolysin O and Escherichia coli Hemolysin A are pore-forming bacterial 
cytotoxins. Each is produced as a water-soluble single-chain polypeptide that inserts into 
target membranes to form aqueous transmembrane pores (186). Interestingly IL-6R shedding 
was not induced by a Streptolysin O mutant that retained cell membrane binding capacity but 
lacked pore-forming activity indicating that disruption of the plasma membrane is essential 
for ADAM activation (80). The exposure of living cells to cyclodextrins (e.g. methyl-β-
cyclodextrins, mβCD) results in cholesterol removal from cell membranes into the 
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hydrophobic cavity of the mβCD molecule (187). Thus mβCD treatment leads to alteration of 
the plasma membrane composition by cholesterol efflux. 
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Figure 36: Stimuli involved in IL-6R shedding.  
IL-6R shedding can be stimulated by the pentraxin family member CRP (C-reactive protein), Streptolysin O and 
Hemolysin A (bacterial pore forming proteins), mβCD (cholesterol depleting agent), PMA (phorbol ester) and 
during extrinsic and intrinsic apoptotic pathways. Note: PMA-induced PKC translocation from the cytosol to the 
plasma membrane leads to a conformational change of the protein. This conformational change results in 
removal of the autoinhibitory pseudosubstrate domain from the active site. Abbreviations: PC: 
phosphatidylcholine, SM: sphingomyelin, cas-8: caspase 8, cas-3: caspase 3, cas-9: caspase 9. 
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During apoptosis drastic membrane changes occur when phosphatidylserine is exposed to the 
exterior of the plasma membrane. Therefore the hypothesis was set up that apoptotic 
pathways might lead to an induction of IL-6R ectodomain shedding. Programmed cell death 
or apoptosis is essential in multi-cellular organisms for development, tissue turnover and host 
defense. In this study we show that the induction of intrinsic and extrinsic apoptotic pathways 
leads to an activation of the metalloproteinase ADAM17, which subsequently leads to IL-6R 
shedding. Therefore apoptotic pathways represent a physiological stimulus for induced IL-6R 
shedding. 
During apoptosis the IL-6R is efficiently cleaved in Ba/F3 [gp130/IL-6] cells, HepG2 cells 
and primary human neutrophils. The soluble 65 kDa ectodomain of the IL-6R was released 
into the cell culture medium after induction of apoptosis by cytokine deprivation, 
doxorubicin, agonistic Fas antibody or UV treatment. The generation of the soluble IL-6R 
during apoptosis was efficiently blocked by GW280264X, a combined ADAM10 and ADAM 
17 inhibitor, whereas the specific ADAM10 inhibitor GI254023X did not prevent IL-6R 
shedding during apoptosis. Moreover transfection of a dominant-negative mutant of TACE 
decreased IL-6R shedding by 30 % in apoptotic HepG2 cells. Although shedding of the IL-6R 
is an early apoptotic process, blockade of ADAM17 did not inhibit apoptosis indicating that 
ADAM17 activity is not required for apoptosis. In this study it was demonstrated that most 
likely cleavage of the prodomain of ADAM17 is involved in ADAM17 activation, since the 
amount of processed ADAM17 protein increased during apoptosis. ADAM17 has been found 
to be transcriptionally up-regulated and to be translocated to the cell membrane during 
apoptosis (188, 189). Increased IL-6R shedding in apoptotic cells treated with the protein 
synthesis inhibitor cycloheximide was detected in this study. Therefore it was excluded that 
ADAM17 protein synthesis was needed for apoptosis-induced shedding of the IL-6R. Thus 
induction of ADAM17 activity appears to occur through an increase in the enzymatic activity 
of constitutively expressed ADAM17 molecules. Earlier studies with transfected COS-7 cells 
revealed that only a minor fraction of ADAM17 protein were present at the cell surface, with 
the majority being localized to a perinuclear region (190), and being translocated to the cell 
surface upon activation (191).  
Induction of apoptosis requires a complex interplay of signaling molecules, receptors and 
enzymes. In the course of apoptosis the activation of caspases is the central step driving cells 
into the execution phase of programmed cell death. Activation of the caspase cascade 
comprising initiator caspases like caspase-8 and caspase-9 and executor caspases like caspase-
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3, finally lead to morphological changes characterized by phosphatidylserine exposure, DNA-
fragmentation and apoptotic body formation (192). This study demonstrates that ADAM17 
activation is dependent on the combined activation of caspases-8, -9 and -3 but independent 
of PKC, a known mediator of PMA-induced shedding. Even though blocking of individual 
caspases did not significantly reduce IL-6R shedding, combined inhibition blocked shedding 
of the IL-6R. Although it is not possible to rule out non-specific effects of the individual 
caspase inhibitors, the results obtained in this study point to a common downstream target of 
caspases -3, -8, and -9 involved in governing ADAM17 activity.   
How is ADAM17 activated during apoptosis finally leading to IL-6R shedding? Most cell 
stimuli that induce shedding of surface molecules appear to require the mitogen activated 
protein kinases (MAPK) or reactive oxygen species (ROS) generation. It was shown that Erk- 
and p38-MAPK are involved in ADAM17 activation during PMA and osmotic stress 
treatment. Moreover ADAM17 directly interacts with the Erk-MAPK after PMA treatment 
which leads to phosphorylation of ADAM17 at threonine735 (108). Besides of the MAPK 
pathway it has been suggested that ADAM17 can be activated by ROS (e.g. H2O2). PMA 
treatment induces ROS generation and ROS scavengers attenuate PMA-induced ectodomain 
shedding (110, 193). During apoptosis proteins of the MAPK family are involved in the 
induction as well in the execution phase of programmed cell death pathways (194, 195). In 
this study we could show that IL-6R shedding during apoptosis is independent of MAPK 
activation. Induction of apoptosis in the presence of specific inhibitors for the p38-MAPK as 
well as for the Erk1/2-MAPK did not block IL-6R shedding. Apoptotic stimuli like UV 
treatment, Fas stimulation and doxorubicin treatment are well known inducer of ROS. 
Therefore we analyzed next the effect of ROS generation on the shedding of the IL-6R during 
apoptosis. Preincubation of HepG2 cells with the ROS-scavengers nPG and DMTU as well as 
the NADPH oxidase inhibitor DPI did not result in inhibition of IL-6R shedding during 
apoptosis. In summary, the molecular mechanism of ADAM17 activation during apoptosis is 
caspase dependent since combined inhibition of caspase-3, -8 and -9 results in diminished IL-
6R shedding. Although well known ADAM17 activators, like proteins belonging to the PKC 
and MAPK family, are either downstream targets of caspases or are activated during apoptotic 
pathways, they do not seem to be involved in ADAM17 activation. ROS can activate latent 
proforms of metalloproteinases. However, ROS did not activate ADAM17 mediated IL-6R-
shedding during apoptosis. Interestingly, a recent study demonstrates that ADAM10 is the 
sheddase responsible for releasing CD46 from apoptotic cells. In contrast to our findings 
regarding ADAM17 activation, Hakulinen et al. could show that ADAM10 activity during 
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apoptosis is ROS dependent (196). Thus besides ADAM17 the close related sheddase 
ADAM10 is activated during apoptosis by a different molecular pathway involving ROS 
generation. 
In a previous study Gómez-Gaviro et al. could show that L-selectin shedding on human 
neutrophils is induced by several nonsteroidal anti-inflammatory drugs (NSAIDs) which lead 
to reduction of intracellular ATP concentration. In line with this finding L-selectin shedding 
was also induced by the metabolic blockers azide and 2-deoxy-D-glucose. The authors claim 
that maintenance of L-selectin on the cell surface requires energy consumption which 
suggests that L-selectin is shed in default of intracellular ATP concentration (111). Similar 
studies regarding the regulating of IL-6R shedding during ATP depleting conditions were not 
performed so far. Nevertheless it is unlikely that cellular ATP reduction is the molecular 
mechanism which induces ADAM17 activation during apoptosis since a high concentration of 
ATP is required for cells to undergo programmed cell death. Moreover levels of intracellular 
ATP determine whether cells die by apoptosis or necrosis. In contrast to apoptosis which is an 
ATP-dependent process, necrosis does not require intracellular ATP.  
 
5.2 The physiologic role of IL-6R shedding during apoptosis 
 
IL-6 mediated signal transduction is involved in induction of growth, differentiation and pro-
survival pathways in different cell types. IL-6 effectively protects gastric cancer cells from 
apoptosis induced by hydrogen peroxide (H2O2) and serves as a growth factor for multiple 
myeloma cells and renal cell carcinoma cells (12, 13, 197). Moreover IL-6 is involved in 
extended neutrophil survival during pathological conditions and serves as major growth 
regulator in the liver following toxic damage, hepatitis and surgical resection (198, 199). The 
anti-apoptotic effect of IL-6 is cooperatively mediated by the PI3K/Akt and STAT3 
pathways. The signaling pathway, from PI3-kinase to the serine/threonine protein kinase 
Akt/protein kinase B (PKB), results in induced mcl-1 gene expression. Mcl-1 belongs to the 
anti-apoptotic Bxl-2 protein family and exerts together with Bcl-2 and Bcl-XL a central role in 
regulating apoptosis (200). The STAT3 pathway regulates growth-promoting genes (cyclin D 
and c-myc) as well as anti-apoptotic genes (survivin and bcl-xl) (201-203).  
Due to the major biological properties of IL-6 to induce cell proliferation and survival it is 
reasonable to argue that IL-6R shedding during apoptosis is important for regulating the 
survival decision of cells undergoing programmed cell death. Shedding of the IL-6R would 
accord to unresponsiveness towards IL-6 during apoptosis. Surprisingly, blocking IL6R 
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shedding from apoptotic cells with the metalloprotease-inhibitor marimastat did not alter the 
STAT3 phosphorylation in the presence of IL-6. During onset of apoptosis Ba/F3 [gp130/IL-
6R] cells became unresponsive to IL-6 in absence or presence of the IL-6R. This result 
indicates that IL-6 mediated signal transduction is terminated during apoptosis by other 
pathways then IL-6R shedding. This was further highlighted by the finding that during 
apoptosis, the mRNA of the negative signalling protein SOCS3 was slightly up-regulated in 
neutrophils and gp130 was down-regulated in hepatocytes, indicating the induction of a 
negative feedback loop for gp130 signalling (204). In addition Hideshima et al. demonstrate 
that the cytoplasmic tail of gp130 is a substrate for caspases. Caspase-mediated cleavage of 
the intracellular part of gp130 results in a signal-transduction defective receptor (205).  
It is reported that IL-6 attenuates spontaneous neutrophil apoptosis (198). Findings in this 
study revealed that IL-6-mediated signalling did not necessarily play a role in the survival 
decision of induced neutrophil apoptosis. The extent of apoptosis of neutrophils after Fas 
stimulation was not altered in the presence of IL-6 or the fusion protein Hyper-IL-6 a 
complex of the IL-6/sIL-6R. It is possible that IL-6 exerts its pro-survival properties only on 
neutrophils undergoing spontaneous apoptosis. Unlike many other cell types, neutrophils 
undergo spontaneous apoptosis without any need for apparent external inductive stimuli. 
However the signal-transduction pathways involved in spontaneous apoptosis remain elusive 
and could probably differ from the pathways involved in induced programmed cell death, like 
Fas ligation or UV treatment. Therefore our finding that IL-6 signalling is rather not involved 
in inhibition of Fas-induced neutrophil apoptosis does not necessarily conflict with previous 
reports. 
IL-6 can elicit responses directly in cells expressing IL-6R/gp130 or, alternatively, a soluble 
form of the IL-6R (sIL-6R) can bind IL-6 and the complex can be recognized by cells 
expressing gp130 alone. This process is known as trans-signalling (50, 51). Because the role 
of IL-6R shedding was not termination of IL-6 signalling the hypothesis was set up that IL-6R 
shedding during apoptosis was importing to stimulate surrounding non-apoptotic cells via IL-
6. Indeed the sIL-6R generated during apoptosis was biologically active and could promote 
IL-6 trans-signalling in Ba/F3 [gp130] cells. Therefore apoptotic cells may represent the 
source of sIL-6R in normal as well as in inflammatory and pathologic conditions.  
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5.3 IL-6R shedding during neutrophil apoptosis: Implication 
during acute inflammation 
 
The sIL-6R is present in the plasma of healthy individuals (25-35 ng/ml) and elevated levels 
of this soluble receptor have been detected in numerous disease states. The confined cellular 
expression of the IL-6R narrow the cell types down to neutrophils, macrophages, B-cells, 
subpopulation of T-cells and hepatocytes, which could represent the source of shed sIL-6R in 
vivo. Neutrophils have been used in this study for several reasons (1) it has been shown in 
previous studies that neutrophils express both the IL-6R and ADAM17 (174, 188), (2) 
neutrophils have the shortest life span of the various leukocytes and die rapidly via apoptosis 
in vivo and in vitro, (3) IL-6R shedding from neutrophils has been associated with activation 
by C-reactive protein, chemokines and other chemotactic agents (53, 78, 175, 206). 
Consistent with the data obtained with HepG2 and Ba/F3 [gp130/IL-6R] cells, human primary 
neutrophils shed the IL-6R upon induction of apoptosis in an ADAM17-dependent manner. 
Interestingly recent studies by Walcheck et al. demonstrate that L-selectin is also shed from 
the cell surface by neutrophils undergoing apoptosis indicating that during programmed cell 
death several proteins are cleaved by metalloprotease activity (188). It has been reported that 
in apoptotic neutrophils ADAM17 expression was up-regulated and that airway neutrophils 
are activated by bacteria leading to the release of sIL-6R possibly via ADAM17 activation 
(174). The data obtained in this study suggest that induction of apoptosis, irrespective of the 
activation stimuli, will lead to activation of the metalloproteinase ADAM17 resulting in 
enhanced IL-6R shedding from the neutrophil surface.  
Soluble IL-6R is found in the serum of healthy individuals. It was shown in previous studies 
that both IL-6R isoforms, the differential mRNA spliced as well as the proteolitically cleaved, 
were circulating in blood obtained from normal healthy individuals (207). Thus it is tempting 
to speculate that apoptotic neutrophils contribute to the circulating sIL-6R level due to 
approximate 1011 short-lived neutrophils are delivered to the blood each day.  
The inflammatory response is characterized largely by influx of neutrophils. These 
phagocytes possess microbicidal capacity and are thus efficient at killing invading 
microorganisms. Although the inflammatory response is highly beneficial to the host, 
coordinated termination is critical to limit tissue damage (208). To avoid tissue damage, 
neutrophils undergo apoptosis following phagocytosis as a mechanism to promote resolution 
of inflammation. The resolution process includes switching from neutrophil to mononuclear 
leukocyte recruitment and mononuclear leukocytes are responsible for removal of apoptotic 
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neutrophils. Appropriate control of the inflammatory infiltrate is reliant upon the coordinated 
regulation of inflammatory chemokines together with a balanced apoptotic clearance of 
immune cells. The switch between the initial neutrophilic stage of inflammation and the later, 
more sustained influx of mononuclear cells involves IL-6 trans-signalling but a trigger for this 
process has remained elusive (209). 
Previously, it was shown that IL-6 trans-signaling in stromal cells including endothelial cells, 
mesothelial cells, smooth muscle cells and fibroblasts differentially regulates the expression 
of inflammatory chemokines including the neutrophil attracting chemokines CXCL8/IL-8 and 
the monocyte attracting chemokines CCL2/MCP1 (210-212). Through clinical evaluation of 
local sIL-6R levels in various inflammatory conditions, it is evident that a close association 
exists between the number of infiltrating neutrophils and sIL-6R levels (175). In this context, 
IL-6R shedding from neutrophils has been associated with activation by C-reactive protein, 
chemokines and other chemotactic agents (53, 78, 175, 206) whereas gp130 is not subject to 
proteolysis by ADAM proteases (213). In this present study, an alternative mechanism is 
offered, whereby apoptosis-induced shedding of IL-6R from the neutrophil surface facilitates 
formation of an IL-6/sIL-6R complex and directs IL-6 trans-signaling presumably on 
endothelial cells to promote recruitment of monocytic cells involved in the nonphlogistic 
removal of apoptotic neutrophils. Thus shedding processes in apoptotic neutrophils may have 
profound affects on the outcome of the inflammatory response. Notably, such a cascade of 
neutrophils and mononuclear cells has been shown to be non-functional in IL-6-/- mice (175, 
214). In this study the air pouch model of acute inflammation was used to analyze leukocyte 
migration during inflammation under various experimental conditions. Injection of the irritant 
carrageenan into dorsal air pouches of mice resulted in a local inflammatory reaction. 
Infiltrating leukocytes were analyzed after a period of 72 hours. The studies revealed that IL-6 
signalling and precisely IL-6 trans-signalling were important for recruitment of mononuclear 
cells into the center of inflammation. Soluble gp130-Fc (inhibitor of trans-signalling but not 
classic signalling) and neutralizing antibodies against the IL-6R (inhibitor of classic signalling 
and trans-signalling) block signalling pathways with are involved in recruitment of 
mononuclear cells. The control animals show 72 hours after injection of the irritant high 
amounts of infiltrated mononuclear cells in the air pouch cavity. In the sgp130-Fc as well as 
in the neutralizing IL-6R-antibody treated mice the mononuclear cell infiltration was strongly 
reduced. Further studies will be needed to analyze which exact molecular pathway is impaired 
in absence of IL-6 trans-signalling. Notably application of sgp130-Fc also reduced the amount 
of infiltrated neutrophils into the inflamed air pouches suggesting that IL-6 trans-signalling is 
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not only important for monocytic but also for neutrophilic attraction during inflammatory 
responses. In previous studies Romano et al. used the air pouch model of acute inflammation 
to analyze leukocyte infiltration in IL-6-deficient (IL-6-/-) mice. The studies revealed that IL-
6-/-mice harboured significantly less leukocytes in the inflamed air pouch compared to the 
wildtype littermates 24 hours after injection of the irritant carrageenan (176). The air-pouch 
experiments performed in the present work with the IL-6-/-mice revealed similar results 
concerning the infiltrating leukocytes in the initial phase of inflammation (12 hours after 
injection of carrageenan). Surprisingly, in the advanced phase of inflammation (72 hours after 
injection of carrageenan) the IL-6-/-mice showed no significant impairment in leukocyte 
migration compared to age-matched wildtype animals. This observation indicate that IL-6-
mediated signal transduction is indispensable during onset of inflammation in agreement with 
previous reports but at later time points leukocyte infiltration is restored by a yet unknown 
mechanism in IL-6-/-mice. It is very likely that the lack of IL-6 is probably compensated by 
the redundancy within the IL-6 system. IL-6 is only one member of a large IL-6 family that 
includes e.g. LIF, CT-1, OSM, CNTF, IL-11 and NNT-1, which share the common receptor 
subunit gp130 for signalling. Further studies are needed to investigate if and which factor is 
responsible for the compensation of IL-6 in IL-6-/-mice during the advanced phase of acute 
inflammation. In previous studies it has been shown that IL-6-/-mice exert severe deficiency in 
several aspects of the acute host response after turpentine treatment, including the liver acute 
phase reaction, anorexia, loss of body weight, and hypoglycaemia. However, the same 
responses were only slightly modified after LPS treatment. The finding that IL-6 was not 
required to generate an inflammatory response to LPS was surprising, as IL-6 is produced in 
large quantities upon LPS injection. The authors speculate that functional redundancy 
between different cytokines, in particular IL-1 and TNF-α, can compensate for IL-6 loss of 
function (215).  
In summary, administration of neutralizing antibodies against the IL-6R as well as sgp130-Fc 
lead to impaired attraction of monocytes to the inflamed area. The results obtained in this 
study support already published observations where administration of blocking antibodies 
against the IL-6R or recombinant sgp130-Fc have proved to moderate leukocyte infiltration 
during pathological conditions like rheumatoid arthritis and peritonitis (175, 210). Therefore, 
the IL-6R system is a likely target for new therapeutics designed to treat inflammatory 
disorder.  
. 
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Figure 37: IL-6 trans-signalling in the switch from neutrophil to mononuclear leukocyte recruitment 
during the resolution of inflammation. 
The inflammatory response involves influx of polymorphonuclear leukocytes (PMNs or neutrophils). 
Phagocytosis of microbes and cell activation ultimately lead to PMN apoptosis (a-PMN), during which 
ADAM17 is activated to cleave the IL-6R from the cell surface (shedding). IL-6 and soluble IL-6R derived from 
apoptotic neutrophils activate signal transduction pathways which lead to recruitment of mononuclear 
phagocytes via IL-6 trans-signalling, possibly through endothelial cells. Phagocytosis of apoptotic neutrophils by 
mononuclear phagocytes, typically macrophages, is a key step in the resolution of acute inflammation. Adopted 
from (216).  
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5.4 Outlook 
 
In this work extrinsic and intrinsic apoptotic pathways were identified as physiological stimuli 
for induced IL-6R shedding in vitro. The sheddase which mediates IL-6R ectodomain 
cleavage during programmed cell death was identified as ADAM17. Although ADAM17 
activation was caspase dependent, the exact molecular mechanism leading to activation of the 
shaddase was not identified in this work. It is a challenge for future studies to identify the 
molecular mechanism which leads to ADAM17 activation during apoptosis. In this work 
already described stimuli, like MAPKs or reactive oxygen species (ROS), were excluded to 
be involved in ADAM17 activation during apoptosis by application of widely used inhibitors.  
Since ADAM17 is responsible not only for shedding of the IL-6R but has also been 
implicated in the cleavage of, for example, TNFα, TGF-α, and various adhesion molecules as 
well as of some cytokine and growth factor receptors (213), it will be interesting to analyze 
whether all these substrates are also shed upon induction of apoptosis. Therefore, further 
experiments will be needed to fully understand the importance of this metalloprotease 
activation step for the progress and outcome of immune responses. Such consequences might 
include altered adhesion, rolling and attraction of neutrophils as well as changes in the 
activation pattern of other immune and non-immune cells. 
The observation that primary human neutrophils shed the IL-6R upon induction of apoptosis 
makes it tempting to speculate that this cell type is the major provider of shed IL-6R in vivo. 
Neutrophils are short live cells, which undergo spontaneous apoptosis during normal 
conditions. During inflammation neutrophils constitute the “first line of defence” against all 
classes of infectious agents but, paradoxically, they are also involved in the pathology of 
various inflammatory conditions. It would be interesting to investigate if the amount of sIL-
6R correlates with the number of circulating or infiltrating neutrophils during normal and 
pathological conditions. If neutrophils represent the major source of shed IL-6R, then the 
level of this protein should be drastic reduced in patients suffering from neutropenia (e.g., 
after chemotherapy). Future experiments with neutrophils deficient in ADAM17 expression, 
will reveal more information about the role of soluble IL-6R, derived from ectodomain 
shedding on neutrophils, during pathological and inflammatory conditions. 
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6 Summary 
 
Interleukin-6 (IL-6) trans-signalling has emerged as a prominent regulator of immune 
responses during both innate and acquired immunity. Regulation of IL-6 trans-signalling is 
reliant upon the release of soluble IL-6R (sIL-6R), which binds IL-6 to create an agonistic IL-
6/sIL-6R complex capable of activating cell types that would normally not respond to IL-6 
alone. Soluble IL-6R is generated by proteolytic cleavage of the membrane-anchored 
precursor (shedding) or from alternative spliced mRNA. Several inducers of IL-6R shedding 
such as bacterial pore forming toxins, bacterial metalloproteases, the phorbol ester PMA, 
cholesterol depleting agents and C-reactive protein have been identified in previous studies. 
IL-6R shedding induced by PMA and cholesterol depletion is dependent on the 
metalloprotease ADAM17 (A Disintegrin And Metalloprotease), and to a lesser extent on the 
related sheddase ADAM10. 
In this study apoptosis was identified as a natural stimulus of IL-6R shedding. Apoptosis, or 
programmed cell death, plays an important role in regulating growth, tissue homeostasis, 
development and immune responses. The induction of apoptosis is mediated by extrinsic and 
intrinsic pathways which require the cooperation of a series of molecules including signal 
molecules and receptors, enzymes and gene regulating proteins. Among them, the caspase-
cascade signalling system is crucial for induction, transduction and amplification of 
intracellular apoptotic signals. This study demonstrates that intrinsic and extrinsic apoptotic 
stimulation of cells by DNA-damage, cytokine deprivation, UV irradiation and Fas ligation 
promotes shedding of the IL-6R from the cell surface thereby generating sIL-6R. Apoptosis-
induced shedding of the IL-6R was caspase dependent but PKC, MAPK and ROS 
independent. Inhibition of ADAM17 during apoptosis by small pharmacological inhibitors or 
a dominant-negative ADAM17 variant resulted in prevention of IL-6R shedding. The sIL-6R 
generated during apoptosis was biological active and formed complexes with IL-6 thereby 
facilitating IL-6 trans-signalling in nonapoptotic cells. 
Neutrophils have a short life span and die rapidly via apoptosis in vivo and in vitro. In this 
study neutrophils were used as a cellular model. Induction of apoptosis by Fas-ligation or UV 
irradiation of primary human neutrophils promoted IL-6R shedding thereby resulting in a 
two-fold increase of sIL-6R release. Neutrophils represent the first cell population infiltrating 
inflamed areas and play a crucial role during inflammatory responses due to their 
extraordinary microbial capacity. Following phagocytosis of invaded microorganisms 
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neutrophils undergo apoptosis as a mechanism to promote resolution of inflammation. The 
second cell population which migrates into the inflamed area consists mostly of mononuclear 
phagocytes (monocytes) which are responsible for the clearance of apoptotic neutrophils thus 
leading to resolution of the inflammatory reaction. Findings in this study indicate that 
apoptosis-induced shedding of the IL-6R from the neutrophils surface facilitates formation of 
an [IL-6/sIL-6R] complex which directs IL-6 trans-signalling presumably on endothelial cells 
to promote recruitment of mononuclear phagocytic cells involved in the nonphlogisic removal 
of apoptotic neutrophils. Using a mouse model of acute inflammation, it was demonstrated in 
this study that blocking IL-6R-mediated signal transduction by neutralizing antibodies or 
soluble gp130-Fc during acute inflammation resulted in a normal influx of neutrophils but a 
severely impaired influx of monocytes into the inflamed area. Therefore, IL-6R shedding and 
subsequent IL-6 trans-signalling represent important steps for the resolution of inflammatory 
responses by controlling the recruitment of mononuclear phagocytes. Thus, shedding of the 
IL-6R during neutrophil apoptosis may have profound effects on the outcome of the 
inflammatory response. 
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7 Zusammenfassung 
 
Interleukin-6 (IL-6) vermitteltes trans-signalling ist ein wichtiger regulatorischer Signalweg 
für die Steuerung der angeborenen und erworbenen Immunität. IL-6 trans-signalling wird 
durch die Freisetzung vom löslichen Interleukin-6-Rezeptor (sIL-6R) moduliert; dieser bindet 
an IL-6, um einen IL-6/sIL-6R Komplex zu bilden. Der Komplex aus IL-6 und sIL-6R kann 
dann Zellen stimulieren, die lediglich gp130 exprimieren und normallerweise nicht in der 
Lage sind auf IL-6 zu reagieren, da ihnen die ligandenbindende Untereinheit (IL-6R) fehlt. 
Die lösliche Form des IL-6Rs kann entweder durch limitierte Proteolyse des 
membranständigen Rezeptors oder durch alternatives Spleißen der IL-6R mRNA generiert 
werden. In vorherigen Arbeiten konnte bereits gezeigt werden, dass die limitierte Proteolyse 
des IL-6Rs (Shedding) durch bakterielle porenformende Toxine, bakterielle Metalloproteasen, 
den Phorbolester PMA, Cholesterinentzug und C-reaktivem Protein induziert werden kann. 
Shedding des IL-6Rs durch Phorbolester und Cholesterinentzug wird hauptsächlich durch die 
Metalloprotease ADAM17 (A Disintegrin And Metalloprotease 17) und zum geringen Teil 
von der verwandten Protease ADAM10 vermittelt. 
Im Rahmen dieser Arbeit konnte gezeigt werden, dass apoptotische Zellen vermehrt den IL-
6R spalten; demnach stellen apoptotische Prozesse einen physiologischen Stimulus für 
induzierte IL-6R Proteolyse dar. Apoptose wird auch als programmierter Zelltod bezeichnet 
und spielt in der Regulation von Zellwachstum, Gewebehomöostase und Immunreaktionen 
eine entscheidende Rolle. Apoptose kann abhängig von der Art des auslösenden Reizes auf 
verschiedene Wege eingeleitet werden; zum einen durch Aktivierung von Todesrezeptoren 
auf der Zellmembran und zum anderen durch mitochondrial vermittelte Signalwege. 
Hauptmerkmal beider Apoptosewege sind Caspasen (Cysteinproteasen), welche die 
morphologischen und biochemischen Merkmale der Apoptose durch Spaltung von zellulären 
Bestandteilen hervorrufen. 
Im Rahmen dieser Arbeit konnte gezeigt werden, dass sowohl todesrezeptoren- als auch 
mitochondrialvermittelte Apoptose zu vermehrter Proteolyse des IL-6Rs führt. Dabei wurde 
zelluläre Apoptose durch verschiedene Wege induziert, wie zum Beispiel durch toxische 
Substanzen, die zur Schädigung des genetischen Materials führen, UV-Bestrahlung, 
Aktivierung des Todesrezeptors CD95 (Fas) oder Entzug von Überlebensfaktoren. Das durch 
Apoptose induzierte IL-6R Shedding war Caspase-abhängig jedoch PKC-, MAPK- und ROS- 
unabhängig. Des Weiteren führte eine Inhibition von ADAM17 durch kleine 
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pharmakologische Inhibitoren oder durch eine dominant-negative ADAM17 Variante 
während des programmierten Zelltodes zur kompletten Unterbindung von 
apoptosevermitteltem IL-6R Shedding. Der lösliche IL-6R, welcher während der Apoptose 
vermehrt gebildet wurde, war biologisch aktiv und konnte im Komplex mit IL-6 in nicht-
apoptotischen gp130 exprimierenden Zellen trans-signalling auslösen.  
Polymorphkernige Neutrophile sind kurzlebige Zellen mit einer Lebensdauer von 6-8 
Stunden; danach sterben Neutrophile durch Apoptose. Im Rahmen dieser Arbeit wurden 
Neutrophile als zelluläres System verwendet. CD95 (Fas) Aktivierung und UV-Bestrahlung 
lösten in primären humanen Neutrophilen Apoptose aus, welche mit erhöhtem Shedding des 
IL-6Rs einherging. Bei Entzündungsprozessen stellen Neutrophile die erste 
Verteidigungslinie gegen Mikroorganismen dar. Neutrophile phagozytieren Mikroorganismen 
und töten diese durch vermehrte Produktion von Sauerstoffradikalen ab. Um die 
inflammatorische Reaktion zu beenden, müssen die aktivierten Neutrophilen eliminiert 
werden. Dies passiert durch die Einleitung von Apoptose in aktivierten Neutrophilen und 
anschließender Phagocytose durch mononukleäre Immunzellen (Monocyten), welche als 
zweite Zellpopulation in den Entzündungsort einwandern. Ergebnisse in dieser Arbeit zeigen, 
dass apoptotische Neutrophile verstärkt den IL-6R spalten. Dieser bildet einen Komplex mit 
IL-6. Der Komplex aus sIL-6R/IL-6 stimuliert daraufhin endotheliale Zellen, Mediatoren 
auszuschütten, die an der Rekrutierung von Monocyten beteiligt sind. Mit Hilfe eines murinen 
Krankheitsmodelles (Air-pouch-Modell) konnte gezeigt werden, dass Blockierung von sIL-
6R-vermittelten Signalwegen durch neutralisierende Antikörper oder rekombinantem 
löslichen gp130-Fc zu einer stark verminderten Akkumulation von Monocyten in den 
Entzündungsherd führt. Demnach wird der sIL-6R von apoptotischen Neutrophilen freigesetzt 
und beeinflusst bei entzündlichen Prozessen die Einwanderung von Monocyten, welche für 
das Beenden der inflammatorischen Reaktion verantwortlich sind. 
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9 Appendix 
 
9.1 Vector maps 
 
 
A. pESL-DN-ADAM17 
 
 
 
 
 
 
 
B. p409b-DN-ADAM17 
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9.2 Oligonucleotides 
 
Nr. Primer Sequence (5`-3`) Remarks 
1 D-ADAM17-up AGCAATAAAGTTTGTGGG  
2 D-ADAM17-dn CAGTGCGGCCGCGCACTTTGTTTCTTTGCTG Not-I site 
 
 
 
 
9.3 Accession numbers 
 
Protein Organism Accession number 
ADAM17 human NM_003183 
IL-6R human NM_000565 
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9.4 Abbreviations 
 
A 
A   Adenine 
ADAM  A Disintegrin And Metalloprotease 
APAF1  Apoptotic Protease Activating Factor 1 
APC   Allophycocyanin 
APS   Ammoniumperoxodisulfate 
ATCC   American Type Culture Collection 
ATP   Adenosine 5'-Triphosphate 
 
B 
BCA   Bicinchoninic Acid 
bp   Base Pairs 
BSA   Bovine Serum Albumine 
 
C 
C   Cytosine 
CBM   Cytokine Binding Module 
CD   Cluster of Differentiation 
cDNA   Complementary DNA  
CHX   Cycloheximide 
CIAP   Calf Intestine Alkaline Phosphatase 
CLC   Cardiotrophin-Like Cytokine 
CNTF   Ciliary Neutrotrophic Factor 
CRP   C-Reactive Protein 
CT-1   Cardiothropin-1 
 
D 
DEAE-Dextran Diethylaminoethyl-Dextran 
DISC   Death-Inducing Signaling Complex 
DMEM  Dulbeccos Modified Eagle Medium 
DMSO  Dimethylsulfoxide 
DMTU  1,3-Dimethyl-2-Thiourea 
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DNA   Deoxyribonucleic Acid 
dNTP   2`-Desoxyribonucleotide-5´-Triphosphate 
DPI   Diphenyleneiodonium Chloride 
 
E 
EDTA   Ethylenediaminetetraacetic Acid 
EGFP   Enhanced Green Fluorescent Protein 
EGF   Epidermal Growth Factor 
ELISA   Enzyme Linked Immunosorbent Assay 
ERK   Extracellular Signal Regulated Kinase 
 
F 
FACS   Fluorescence Activated Cell Sorter 
FADD   Fas-Associated Death Domain 
FCS   Fetal Calf Serum 
FITC   Fluorescein Isothiocyanate 
FN III   Fibronectin Type III 
 
G 
x g   g-force 
G   Guanosine 
gp130   Glycoprotein 130 
GPCR   G-protein Coupled Receptors 
Grb2   Growth Factor Receptor Bound Protein 2 
 
H 
HB-EGF  Heparin Binding-Epidermal Growth Factor 
HIL-6   Hyper-IL-6 
HlyA   Hemolysin A 
 
I 
Ig-domain  Immunoglobulin-Domain 
i.p.-injection  Intraperitoneal-Injection 
IVC   Individually Ventilated Cages 
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J 
JRA   Juvenile Rheumatoid Arthritis   
 
L 
LB   Lysogeny Broth 
LIF   Leukaemia Inhibitory Factor 
 
M 
MAPK   Mitogen-Activated Protein Kinase 
mβCD   Methyl-β-Cyclodextrin 
mg   Milligram 
µg   Microgram 
 
 
N 
NADPH  Nicotinamide Adenine Dinucleotide Phosphate 
NP   Neuropoietin 
nPG   n-Propyl-Gallete 
NSAID  Non-Steroidal Anti-Inflammatory Drug 
 
O 
OD   Optic Density 
OSM   Oncostatin M  
 
P 
PARP   Poly ADP ribose polymerase 
PBS   Phosphate Buffered Saline 
PC   Phosphatidylcholine 
PCR   Polymerase Chain Reaction 
PDK1   3-Phosphoinositide-Dependent Protein Kinase 1 
PIAS   Protein Inhibitors of Activated STAT 
PKC   Protein Kinase C 
PMA   Phorbol 12-Myristate 13-Acetate 
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PMN   Polymorphonuclear cells 
PMSF   Phenylmethylsulfonylfluoride 
p-STAT3  Phospho-STAT3 
PVDF   Polyvinylidene Fluoride 
 
R 
RA   Rheumatoid Arthritis 
RNA   Ribonucleic Acid 
ROS   Reactive Oxygen Species 
Rpm   Rounds Per Minute 
RT-PCR  Reverse Transcriptase PCR 
 
S 
SD   Standard Deviation 
SDS   Sodium Dodecyl Sulfate 
SDS-PAGE  SDS-Polyacrylamide Gel Electrophoresis  
sgp130  Soluble gp130 
SH2-domain  Src Homology-2 Domain 
SHP-2   Src homology protein 2 tyrosine phosphatase-2 
sIL-6R   soluble IL-6R 
SLO   Streptolysin O 
SM   Sphingomyelin 
SOCS   Suppressors Of Cytokine Signalling  
SOS   Son Of Sevenless 
STAT   Signal Transducers and Activators of Transcription   
SVMP   Snake Venom Metalloproteinase 
 
T 
T   Thymine 
TACE   Tumor Necrosis Factor-Alpha Converting Enzyme 
TAPI N-(R)-[2-(Hydroxyaminocarbonyl)Methyl]-4-Methylpentanoyl-L-t-
Butyl-Alanyl-L-Alanine, 2-Aminoethyl Amide 
TBE   Tris Borat EDTA    
TBS   Tris Buffered Saline 
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TEMED  N,N,N',N'-Tetramethylethylenediamine 
TGF   Transforming Growth Factor 
TM   Melting Temperature 
TNF   Tumor necrosis factor 
 
U 
U   Units 
UV   Ultraviolet 
 
V 
v/v   Volume per Volume 
vIL-6    Viral interleukin-6 
VDAC   Voltage-Dependent Anion Channel 
 
W 
w/v   Weight per Volume 
WT    Wildtype 
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